

# **Computational Screening and Binding Analysis of Novel Emerging Small-Molecule S1PR1 Modulators for Multiple Sclerosis**

**A Dissertation  
Submitted in partial fulfillment of the requirement of the degree of**

**Master of Science**

**in**

**BIOTECHNOLOGY**

**by**

**Tanishka**

**24/MSCBIO/59**

**Under the supervision of**

**Prof. Pravir Kumar**



**Department of Biotechnology  
DELHI TECHNOLOGICAL UNIVERSITY  
(Formerly Delhi College of Engineering)  
Shahbad Daultapur , Bawana Road , Delhi -110042, India**

**May, 2026**

## **ACKNOWLEDGEMENTS**

As I submit my M.Sc. dissertation, I want to sincerely thank God for providing me with the fortitude, perseverance, and resolve I needed to do this task effectively. Without the help and direction, I had along the way, this journey would not have been possible. It has been both difficult and rewarding.

I am deeply thankful to my mentor, Prof. Pravir Kumar, Department of Biotechnology, Delhi Technological University, for giving me the opportunity to work under his supervision. His guidance, thoughtful suggestions, and consistent encouragement helped me stay focused and improve my work at every stage. His approach toward research and problem-solving has been a valuable learning experience for me, which I will carry forward in my academic and professional journey.

I also want to express my gratitude to my friends and family for their steadfast support. Their encouragement, compassion, and belief in me kept me motivated during the difficult portions of this project. Their presence made this demanding process much more manageable and meaningful.

All things considered, my dissertation has been a tremendous learning experience, and I am appreciative of everyone who helped me finish it, whether directly or indirectly.

**TANISHKA  
24/MSCBIO/59**



**DELHI TECHNOLOGICAL UNIVERSITY**  
(Formerly Delhi college of Engineering)  
Shahbad Daulatpur, Main Bawana Road, Delhi-42

### **DECLARATION**

I, Tanishka, 24/MSCBIO/59 hereby certify that the work which is being presented in the thesis entitled “**Computational Screening and Binding Analysis of Novel Emerging Small-Molecule S1PR1 Modulators for Multiple Sclerosis**” in partial fulfillment of the requirements for the award of the Degree of Master of Science , submitted in the Department of Biotechnology , Delhi Technological University in an authentic record of my own work carried out during the period from 2024 to 2026 under the supervision of Prof. Pravir Kumar.

The matter presented in the thesis has not been submitted by me for the award of any other degree of this or any other Institute.

**Candidate’s Signature**



## **DELHI TECHNOLOGICAL UNIVERSITY**

(Formerly Delhi college of Engineering)  
Shahbad Daultapur, Main Bawana Road, Delhi-42

### **CERTIFICATE BY THE SUPERVISOR**

This is to certify that the Dissertation project titled “ Computational Screening and Binding Analysis of Novel Emerging Small-Molecule S1PR1 Modulators for Multiple Sclerosis” which is being submitted by Tanishka 24/MSCBIO/59, Department of Biotechnology , Delhi Technological University , Delhi in partial fulfillment of the requirement for the award of the degree of Master of Science is a record of the work carried out by the student under my supervision. To the best of my knowledge, this work has not been submitted in part or full for any Degree or Diploma to this University or elsewhere.

Date:

**Prof. Yasha Hasija**  
Head of Department  
Department of Biotechnology  
Delhi Technological University

**Prof. Pravir Kumar**  
Supervisor  
Department of Biotechnology  
Delhi Technological University

# “Computational Screening and Binding Analysis of Novel Emerging Small-Molecule S1PR1 Modulators for Multiple Sclerosis”

TANISHKA  
24/MSCBIO/59

## ABSTRACT

**Aim:** Multiple sclerosis (MS) is a chronic neurological disorder that develops when the body's immune system mistakenly attacks the central nervous system. As a result, the myelin coating that envelops nerve fibers is damaged, which eventually impairs brain-to-body communication. This eventually results in increasing neurological issues like cognitive decline, coordination issues, and muscular weakening. Inflammation, demyelination, and axonal degeneration are the disease's hallmarks, which make it complicated and difficult to treat. Instead of offering a full recovery, current treatment approaches mostly focus on treatments which will modify the disease, which try to slow the course of the illness and regulate immune system activity. Treatments that target sphingosine-1-phosphate receptors (S1PRs), particularly S1PR1, have demonstrated significant potential. These receptors are crucial for controlling lymphocyte migration. In order to lessen inflammatory damage, autoreactive immune cells can be stopped from leaving lymph nodes and entering the CNS by adjusting S1PR1 activity. The first oral medication authorized for the treatment of multiple sclerosis was fingolimod (FTY720), which marked a significant departure from injectable treatments. It has been shown to be successful in lowering relapse rates and functions as a functional modulator of S1PR1. Furthermore, the medication has to be phosphorylated by the body in order to become active, which might have an impact on its overall effectiveness and response consistency among various people. Given these constraints, it is imperative to investigate alternative S1PR1 small-molecule modulators that have better pharmacological and safety characteristics. A computational method was employed in this investigation to find possible compounds that could function as efficient S1PR1 modulators. Molecular docking methods were used to investigate compounds that were selected based on their structural similarity to fingolimod in order to assess their binding interactions with the target protein. Promising possibilities were identified by closely examining the stability and intensity of these interactions. Additionally, significant drug-like characteristics such absorption, distribution, metabolism, and excretion were evaluated by ADME study. These substances might be promising avenues for the creation of safer and more efficient multiple sclerosis medicines.

**Keywords**— Multiple Sclerosis; S1PR1; FTY720; conformation-Based therapeutic Design; Molecular Docking; Auto Dock Vina; Small-Molecule Modulators

**RESULTS** - The molecular docking study revealed that all selected compounds showed favourable binding with the S1PR1 receptor, confirming the suitability of the designed scaffold for Multiple Sclerosis drug targeting. Among them, ligand 6 demonstrated the strongest and most stable interaction, making it a promising lead candidate for further experimental validation.

**CONCLUSION** : With the greatest binding affinity and BBB permeability, ligand 6 is the most effective of the six discovered ligands. We advise using in vivo investigations to confirm these results.

## LIST OF PUBLICATIONS

### 1. Conference Paper

Title of paper -“Computational Screening and Binding Analysis of Novel Emerging Small-Molecule S1PR1 Modulators for Multiple Sclerosis”

Author Names - Tanishka and Prof. Pravir Kumar

Name of the conference - Conference on Latest Innovations in Computing and Knowledge 2026 (CLICK 2026) Hindustan Institute of Technology and Science, Tamilnadu, India.

Date of Conference - 16th to 17th July 2026 at Hindustan Institute of Technology and Science, Tamilnadu, India

Indexing – IEEE

Status of paper – Accepted

Date of Acceptance – 30 April, 2026

## TABLE OF CONTENTS

<b>Title</b>	<b>i</b>
<b>Acknowledgement</b>	<b>ii</b>
<b>Declaration</b>	<b>iii</b>
<b>Supervisor’s certificate</b>	<b>iv</b>
<b>Abstract</b>	<b>v</b>
<b>List of publications</b>	<b>vi</b>
<b>List of Figures</b>	<b>viii</b>
<b>List of Tables</b>	<b>viii</b>
<b>Abbreviations</b>	<b>ix</b>
<b>1. Introduction</b>	<b>1</b>
<b>2. Literature Review</b>	<b>2</b>
2.1 Multiple Sclerosis: Pathophysiology and Disease Mechanism	2
2.2 Blood–Brain Barrier Dysfunction and Neuroinflammation	4
2.3 Role of Sphingosine-1-Phosphate Receptors (S1PR1) in MS	7
2.4 Current Therapeutic Strategies Targeting S1PR1	8
2.5 Advances in Small-Molecule S1PR1 Modulators	11
2.6 Remyelination and Neuroprotective Mechanisms	13
2.7 Structural and Functional Insights into S1PR1	13
2.8 Computational Drug Discovery Approaches	<b>15</b>
2.8.1 Molecular Docking: Principles and Applications	15
2.8.2 Virtual Screening Techniques	15
2.8.3 ADME and Drug-Likeness Prediction	15
2.8.4 Limitations of Computational Methods	16
2.9 Research Gap and Study Rational	16
<b>3. Methodology</b>	
3.1 Retrieval of S1PR1 Protein Structure	17
3.2 Preparation of Target Protein	18
3.3 Selection and Retrieval of Ligands	19
3.4 Ligand Preparation	21
3.5 Molecular Docking Procedure	23
3.6 Binding Interaction Analysis	26
3.7 ADME and Drug-Likeness Analysis	27
<b>4. Results and Discussion</b>	
4.1 ADME Analysis and Initial Screening	29
4.2 Visualizing Ligands in Docked Positions	30
<b>5. Conclusion</b>	<b>37-38</b>
<b>References</b>	<b>39</b>

## LIST OF FIGURES

S.NO.	Title of Figures	Page Number
1	Interaction between ligand no.1 2-amino-2-[2-(4-octylphenyl) ethyl] propane-1,3-diol i.e. Reference compound and target S1PR1	34
2	Interaction between ligand no. 2 4-[(1S,2R)-1-hydroxy-2-[(2R)-1-phenoxypropan-2-yl] amino] propyl] phenol and target S1PR1	34
3	Interaction between ligand no.3 [(3Ar,6As)-5-phenylmethoxy-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl]-[4-(2-aminoethyl) phenyl] methanone with target S1PR1	35
4	Interaction between ligand no. 4 2-[(2R)-4-[[4-(2-phenylethoxy) phenyl] methyl] morpholin-2-yl] ethanamine with target S1PR1	35
5	Interaction between ligand no.5 (1R)-1-[1-[[4-(2-aminoethyl) phenyl] methyl] piperidin-4-yl]-2-phenylethanol and target S1PR1	36
6	Interaction between ligand no. 6 [(1R,3S)-1-amino-3-[(6R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl]cyclopentyl]methanol and target S1PR1	36

## LIST OF TABLES

S.NO.	Title of Table	Page Number
1	TABULAR REPRESENTATION OF IUPAC NAMES, 2D STRUCTURE AND BINDING AFFINITIES OF INTERACTING LIGANDS	31-33
2	TABULAR REPRESENTATION OF ADME ANALYSIS OF INTERACTING LIGANDS	37

## LIST OF ABBREVIATIONS

MS	Multiple Sclerosis
CNS	Central Nervous System
BBB	Blood Brain Barrier
S1P	Sphingosine-1-Phosphate
S1PR1	Sphingosine-1-Phosphate Receptor 1
S1PR	Sphingosine-1-Phosphate Receptor
GPCR	G Protein-Coupled Receptor
OPC	Oligodendrocyte Precursor Cell
ROS	Reactive Oxygen Species
RNS	Reactive Nitrogen Species
IFN- $\gamma$	Interferon Gamma
IL	Interleukin
TNF- $\alpha$	Tumour Necrosis Factor Alpha
CD	Cluster of Differentiation
Th	T Helper Cell
MMP	Matrix Metalloproteinase
ICAM-1	Intercellular Adhesion Molecule-1
VCAM-1	Vascular Cell Adhesion Molecule-1
ZO-1	Zonula Occludens-1
DNA	Deoxyribonucleic Acid
RNA	Ribonucleic Acid
ATP	Adenosine Triphosphate
PI3K	Phosphoinositide 3-Kinase
Akt	Protein Kinase B
MAPK	Mitogen-Activated Protein Kinase
ERK	Extracellular Signal-Regulated Kinase
RRMS	Relapsing-Remitting Multiple Sclerosis
SPMS	Secondary Progressive Multiple Sclerosis
PPMS	Primary Progressive Multiple Sclerosis

FDA	Food and Drug Administration
EMA	European Medicines Agency
ADME	Absorption, Distribution, Metabolism, Excretion
LogP	Partition Coefficient
MW	Molecular Weight
HBD	Hydrogen Bond Donor
HBA	Hydrogen Bond Acceptor
QSAR	Quantitative Structure Activity Relationship
SAR	Structure Activity Relationship
PDB	Protein Data Bank
RMSD	Root Mean Square Deviation
kcal/mol	Kilocalories per Mole
HTS	High Throughput Screening
VS	Virtual Screening
SBDD	Structure-Based Drug Design
LBDD	Ligand-Based Drug Design
PK	Pharmacokinetics
PD	Pharmacodynamics
CNSP	Central Nervous System Penetration
BBBP	Blood Brain Barrier Permeability
SM	Small Molecule

## 1. INTRODUCTION

In most cases, the immune system can be misdirected and attack the insulation that surrounds nerves. The central nervous pathway is struck by trouble, which accumulates slowly, causing irritation and wear. Wounded shielding causes messages along nerves to be dragged by tripping. In the beginning the symptoms show themselves in fits, so as to come like flashes. Initially, symptoms arise and disappear, appearing in waves. As time goes by, skills can be lost forever. What starts in fragments becomes constant, and leaves an indelible imprint on motion, and feeling. The harm accumulates, even in cases where there is no apparent external noise. The ways of the mind are losing, not aged but wrongly assailed. MS occurs when the immune system malfunctions as the brain cells break down simultaneously [1-4]. Scattergun, some white blood cells get awakened - T cells and B cells, among others, and slide under the protective wall that surrounds the brain. After entering them, they generate inflammation waves in nerve areas. The injuries appear quickly: myelin is lost, nerves are injured, certain neurons perish. Such alterations accumulate, making a person more disabled with the years [3,4]. The wall to safeguard leaks better now, and letting in more mischief-makers. Whenever it is breached, the damage is just a little more distant [10,11].

In recent years, novel therapies which modify the course of disease progression have emerged, particularly those which modify immune responses to postpone the onset of exacerbations. These are drugs that target the sphingosine-1-phosphate receptor group, which have actual potential to modulate immunity [12-14]. Located on cell surfaces, S1PRs are part of a broader receptor category associated with numerous body processes - immune movement, blood vessel stability, formation of new vessels, even cell life or cell death [15-17]. A single one of these, S1PR1, is of the greatest importance in directing the white blood cells out of the glands such as lymph nodes, and into the bloodstream [18,19]. Trapping of rogue immune cells in lymph node occurs following a change in S1PR1 activity to prevent their journey to the brain and alleviate nerve inflammation [20,21].

Fingolimod (FTY720), the initial pill-based therapy against this pathway, substituted older needle-based treatments to multiple sclerosis patients - a definite turning point [13,14]. Fingolimod is converted into its active form in an enzyme called sphingosine kinase 2 once it is inside the body. That modified molecule mimics natural signals, however, pulls S1PR1 receptors off cell surfaces and flags them to be destroyed, preventing lymphocytes to move about freely [24,25]. The adverse effects of fingolimod include heart issues, swelling of the eye and high vulnerability to infections, although it is effective in treatment [26-28]. Its unknown location of strike in the body - although it must be converted into the body - can obscure its safety of action [29].

Newer options, including Siponimod and ozanimod, fill this empty space: they target their effect more precisely, and are less likely to cause undesirable reactions [30 -32]. S1P signalling is no longer implicated in the control of immune responses, but now also involved in the protection of nerve cells, in the promotion of myelin-generating cells, and also in repair of damaged neural areas - indicating a dual role in immunity and brain repair [33-35]. These outcomes led to the fact that, the idea of S1PR1 as a target in treating multiple sclerosis has taken traction, particularly in the development of specific, simplified drug-like molecules as opposed to generalized agents.

The digital technologies in molecule docking and absorption screening have gained critical importance as a part of the first stage of medicine hunting due to computer-based biology. Instead of trying to test it at the lab at once scientists model the behaviour of small fragments binding to proteins. This helps to weed out bad candidates in one way or another, and also bring out the good ones in bodies. The consequence of this change is a decrease in the number of lab tests that are necessary at the beginning - time and energy saving [36-38-55]. In research, multiple sclerosis can be studied using these tools to narrow down the discovery of new compounds to S1PR1 switch. Some of these molecules attach more firmly, target the inappropriate sites and find their ways in tissues easier than the older molecules.

This analysis is reduced to computer-based testing and interaction assays of new tiny molecules in S1PR1. It uses simulated placement of molecules, absorption, and metabolism predictions to hunt compounds that have the potential to substitute existing Multiple Sclerosis therapies. The search is fuelled by safer profiles and better performance. Results can indicate solutions that are more patient-oriented. Exploration speculates on the nature of behaviour of these substances in the body. These are predicted to move. Every action eliminates the potential competitors [55–58].

## 2. LITERATURE REVIEW

### *2.1 Multiple Sclerosis: Pathophysiology and Disease Mechanism*

When multiple sclerosis develops, strange changes take place within the body. This is an incurable disease that mainly impacts on the nervous system. Its development differs with individuals, depending on their genetic disposition and exposure to the environment [1]. The immune system instead of defending the body wrongly attacks the body tissues. With the weakening of the myelin, trauma develops, and scar tissue forms and the nerves are harmed. The impairment of functions like movement, sense, and vision occurs in unpredictable ways, over time.

Destruction occurs at sites of lost myelin, leading to plaques and impaired nerve signalling. These transformations progress slowly and there are no obvious symptoms of their occurrence and the development of the disease is different in each person. In its simplest form, multiple sclerosis is the loss of normal immune response towards the myelin sheath around the nerve fibre. This is a sheath generated by oligodendrocytes and promotes the speed at which electrical signals are passed. Inflammation causes demyelination, which slows down or completely stops the conduction of signals. Recurrent rounds of injury and partial repair ultimately lead to the loss of axons and neurodegeneration [2]–[4].

#### **2.1.1 Etiological Factors and Disease Triggers**

Multiple sclerosis has no known cause but there are various factors that have been associated with it. A significant role is played by genetic predisposition, especially variations in genes that regulate the immune system like HLA-DRB1 [5]. The environmental factors play an important role as well. Increased risk has been linked to low levels of vitamin D which is usually as a result of insufficient sunlight exposure. Disease onset is strongly connected with viral infections, in particular, Epstein-Bar virus [6].

Other lifestyle diseases like smoking increase the risk of getting MS. Also, geographical distribution patterns indicate that geography affects disease prevalence. All these factors combined modify the behaviour of the immune systems and ultimately lead to autoimmune reactions against central nervous system. Genetic and environmental factors interact to predispose and modulate disease and symptoms [7].

### **2.1.2 Immune System Dysregulation**

In multiple sclerosis, autoreactive T and B cells (immune tolerance failure) are activated. Th1 and Th17 T helper cells (CD4+) have a central role in the initiation of disease. Th1 cells secrete interferon-gamma (IFN- $\gamma$ ) which stimulates macrophages and Th17 cells secrete interleukin-17 (IL-17) which stimulates inflammation and immune cell recruitment into the CNS [8], [9].

Neurons and oligodendrocytes are directly harmed by CD8+ cytotoxic T cells. B cells also contribute to the production of autoantibodies, the release of cytokines, and the presentation of antigens. Oligoclonal bands of the cerebrospinal fluid indicate enduring immune reactions in the CNS. These immune responses result in an inflammatory lesion or plaque, which is characteristic of multiple sclerosis pathology [10], [11].

### **2.1.3 Demyelination and Lesion Formation**

White matter areas are the main sites of demyelination, where the immune mediated assaults destroy the myelin and oligodendrocytes. Grey matter participation has also been found to be significant in recent studies [12]. MS lesions are characterized by:

- Loss of myelin
- Infiltration of immune cells
- Activation of microglia and astrocytes
- Axonal injury

Such plaques interfere with neural communication and are highly associated with clinical symptoms noted in patients [13].

### **2.1.4 Axonal Damage and Neurodegeneration**

The axonal damage is predominant as the disease advances. The combination of inflammatory attacks, metabolic stress and decreased trophic support causes irreversible damage to nerve fibres. After axons have been cut, a functional recovery is not possible, which adds to permanent neurological impairments [14], [15].

Atrophy of the brain is caused by loss of axons as well as degeneration of neurons. This results in mental deterioration, motor coordination and sensory weakness. Long-term disability in MS patients is greatly affected by the progressive neurodegeneration [16].

### **2.1.5 Mitochondrial Dysfunction and Oxidative Stress**

It is also becoming evident that the mitochondrial dysfunction is becoming a significant player in development of MS. The damaged mitochondria produce less ATP, causing neuronal and glial energy deficiencies. This cellular homeostasis and ionic disturbance [17].

Excessive generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) kills lipids, proteins, and DNA. It is an oxidative stress which facilitates neurodegeneration. This is further increased by impaired mitochondria that leads to a cycle of cell injury that further adds to the development of the disease [18], [19].

### **2.1.6 Clinical Course and Disease Progression**

Multiple sclerosis has a heterogeneous clinical course in various individuals. Others experience mild symptoms and others develop rapid disabilities. The most common form is the relapsing-remitting MS (RRMS) that is characterized by intervals of neurological disabilities and recoveries [20].

RRMS is normally succeeded by secondary progressive MS (SPMS) that is marked by progressive degeneration of the nervous system and fewer relapse. Primary progressive MS (PPMS) on the other hand presents itself with a progressive deterioration of the disease since its onset with no distinct relapses [21].

At the increasing phase of disease, neurodegeneration becomes predominant factor, and inflammation subsides. Such transformation demonstrates the importance of early diagnosis and management of the illness to prevent irreparable harm and improve the long-term outcomes [22].

## ***2.2 Blood Brain Barrier Problems and Brain Inflammation***

The blood-brain barrier (BBB) is a special structure which regulates most of the substances entering the brain. This wall is a discriminative gateway to the central nervous system. It is produced by an intricate system of endothelial cells that envelop the brain capillaries that are not free to permit free passage of undesirable substances. The stability of this structure is supported by astrocytic end-feet which surround the vessels and pericytes. This system is reinforced by a basement membrane. These elements combine to create a very well-coordinated system that only permits necessary molecules to move but blocks harmful agents [23].

The BBB is a physical and biochemical barrier under normal conditions, which does not allow the entry of immune cells and ensures the homeostasis of the nervous system. But, in multiple sclerosis, this protective system is early impaired in the initial phases of the illness. The permeability is increased, which permits the entry of harmful substances and immune cells into the CNS triggering inflammation and consequent neural damage [24].

### **2.2.1 Structural and Functional Alterations**

In the case of multiple sclerosis, the BBB integrity is impaired because of the inflammatory signalling, endothelial dysfunction, and molecular changes. These modifications make the barriers more permeable and allow immune cells to enter the CNS.

Key structural changes include:

- **Disruption of tight junction proteins:**  
BBB integrity is ensured by proteins like claudins, occluding and zonula occludens (ZO-1). Their organization is disturbed by the inflammatory cytokines in MS which enhances paracellular permeability [25].
- **Upregulation of adhesion molecules:**  
Endothelial cells express higher levels of adhesion molecules such as ICAM-1 and VCAM-1, promoting leukocyte adhesion and migration into the CNS [26].
- **Enhanced endothelial permeability:**  
The inflammatory mediators can modify the endothelial activity, enhancing transcellular movement and extravasation of plasma elements into the CNS [27].
- **Matrix metalloproteinase (MMP) activation:**  
MMPs destroy extracellular matrix and basement membrane, weakening BBB, and facilitating immune infiltration [28].

All these effects lead to a weakened BBB that allows the penetration of autoreactive immune cells into the CNS to cause inflammatory reactions [29].

### 2.2.2 Mechanisms of Immune Cell Transmigration

The **migration of immune** cells across the BBB is a highly regulated process with multiple steps that entail sequential interactions between the circulating **leukocytes and endothelial cells**.

First, the leukocytes are rolled through adhesion, which is mediated by selectin molecules on the endothelial surfaces. This is succeeded by the hard sticking, the integrins adhere strongly to ICAM-1 and VCAM-1 and fix the attachment [30].

Then, leukocytes experience transmigration, by passing between cells (paracellular) or across cells (transcellular) across the endothelial layer. The chemokine gradients that steer the immune cells towards the areas of inflammation guide this process [31].

Lastly, the immune cells infiltrate the basement membrane and gain access into the CNS parenchyma where they build up and cause tissue damage. This carefully controlled process is dysregulated in multiple sclerosis, which means that autoimmune cells can gain access to the CNS without any restrictions [32].

### 2.2.3 Inflammatory Cascade

After BBB impairment, inflammatory cascade within CNS is self-amplifying, triggered by infiltrating immune cells. T cells, B cells and macrophages are activated and release pro-inflammatory cytokines, which increase the intensity of the immune response.

Key cytokines involved include:

- Tumor necrosis factor-alpha (TNF- $\alpha$ )
- Interleukin-1 beta (IL-1 $\beta$ )
- Interferon-gamma (IFN- $\gamma$ )
- Interleukin-6 (IL-6)

These cytokines contribute to:

- Recruitment of additional immune cells
- Increased permeability of blood brain barrier
- Activation of resident glial cells
- Damage to oligodendrocytes

The chemokines involved include CCL2 and CXCL10 which direct the immune cells to the inflamed area resulting in the formation of lesions typical of MS [33], [34].

This triggers a loop of immune activation in which inflammation is perpetuated by the ongoing activation of the immune system leading to eventual neural damage with time [35].

#### **2.2.4 Role of Glial Cells in Neuroinflammation**

The glial cells and especially the microglia and astrocytes are important in maintaining neuroinflammation in multiple sclerosis.

##### **Microglia Activation**

Microglia act as resident immune cells of the CNS. In MS, they become chronically activated and contribute to disease progression by:

- Releasing pro-inflammatory cytokines
- Producing reactive oxygen species (ROS) and reactive nitrogen species (RNS)
- Phagocytosing myelin debris and damaged cells

Although it is initially protective, long-term activation results in additional inflammation and neuronal damage [36].

##### **Astrocyte Reactivity**

Astrocytes are generally involved in the support of neurons and in BBB integrity. But as the MS progresses, they are reactive and add to the pathology.

Reactive astrocytes:

- Secrete inflammatory mediators
- Promote gliosis and scar formation
- Inhibit axonal regeneration and remyelination

The formation of glial scar produces a physical and biochemical barrier, which inhibits neural repair and recovery[37].

#### **2.2.5 Oxidative Stress and Secondary Damage**

CNS inflammation causes excess production of reactive oxygen species (ROS) and reactive nitrogen species (RNS), which causes oxidative stress. These reactive molecules cause damage to critical components of the cell, such as:

- Lipids (lipid peroxidation)
- Proteins (oxidative modification)
- DNA (genomic instability)

Such oxidative damage increases neuronal damage and mitochondrial dysfunction, aiding in the continued neurodegeneration and progression of the disease [38], [39].

## **2.3 Role of Sphingosine-1-Phosphate Receptors (S1PR1) in MS**

Sphingosine-1-phosphate (S1P) is a bioactive lipid signalling molecule that controls various physiological functions. It is very important in the immune cell trafficking, vascular integrity, angiogenesis and cell survival. The action of S1P is through binding to a group of five G-protein-coupled receptors, S1PR1-S1PR5, which are tissue-specifically expressed and functionally diverse [40].

S1PR1 is one of these receptors that have been of much interest because it is the centre of both immune regulation and vascular stability. It is also expressed strongly on lymphocytes, endothelial cells and some types of neural cells, which is why it is specifically important in autoimmune diseases including multiple sclerosis [41]. The role of S1PR1 is observed when the immune control mechanism is lost and the inflammatory response starts.

The S1P-S1PR1 signalling axis has been shown to be dysregulated in the pathogenesis of multiple sclerosis. The abnormal signalling facilitates the immigration of immune cells across blood-brain barrier, which plays a role in neuroinflammation. Though the exact mechanisms remain to be studied, changes in this pathway are constantly noted in the case of MS patients. S1PR1 has a therapeutic potential that has been shown to respond differently based on the stage of the disease and biological differences [42].

### **2.3.1 Lymphocyte Trafficking and Immune Regulation**

Controlling the lymphocyte's migration from lymphoid organs into the circulation requires S1PR1.

An S1P concentration gradient is present under normal conditions, where in the lymphoid tissues, the concentration is low, and in the blood and lymph, the concentration is high. This gradient causes the lymphocytes to be driven towards the circulation due to the movement of the lymphocytes along the S1P concentrations that are increased [43].

The S1PR1 is expressed on the surface of lymphocytes and helps them to sense this gradient and to leave the lymph nodes. This is required in immune surveillance and correct immune functioning.

This mechanism is pathogenic in multiple sclerosis. S1PR1-mediated pathway is used by autoreactive lymphocytes to leave lymphoid organs and enter the central nervous system. Once in, they cause inflammatory processes which result in demyelination and neuronal damage [44], [45].

S1PR1 signalling can be modulated to entrap lymphocytes in lymphoid tissues to limit their migration into the CNS. This will lead to reduced inflammation and better disease outcomes.

### **2.3.2 Intracellular Signalling Pathways of S1PR1**

S1PR1 leads to the activation of intracellular signalling cascades upon binding of S1P using Gi-type G proteins. These include:

- PI3K/Akt pathway: Promotes cell survival and anti-apoptotic signalling
- MAPK/ERK pathway: Regulates cell proliferation and differentiation
- Rac/Rho signalling: Controls cytoskeletal dynamics and cell migration

Together, these pathways regulate lymphocyte trafficking, endothelial function, and cellular responses to stress. Disruption of these signalling pathways in MS results in immune imbalance and vascular dysfunction[46].

### **2.3.3 Vascular Stability and BBB Integrity**

S1PR1 plays a very important role in ensuring the structural and functional integrity of the blood-brain barrier. It improves the junction of endothelial cells and tight junction protein like claudins and occluding, which decreases the vascular permeability.

This results in:

- Reduced vascular permeability
- Strengthened endothelial barrier function
- Prevention of excessive immune cell infiltration

In multiple sclerosis, the loss of S1PR1 signalling affects the integrity of the BBB, enabling immune cells to enter the CNS. The effect of inflammatory mediators is also to worsen the breakdown of the barrier by further hindering the functioning of the receptors [47], [48].

Because of its key role in vascular stability, S1PR1 modulation is a promising approach to restoring BBB functions and decreasing neuroinflammation.

### **2.3.4 Neuroprotective and Reparative Functions**

S1PR1 signalling contributes significantly to neuroprotection and repair mechanisms within the CNS. Its activation supports several critical processes:

- Oligodendrocyte survival
- Remyelination of damaged nerve fibers
- Neuronal survival through anti-apoptotic signalling
- Maintenance of synaptic stability

Activation of intracellular pathways such as PI3K/Akt enhances cell survival and reduces oxidative damage. These processes aid in reversing neuronal death and metabolic disease. S1PR1-mediated signalling is anti-inflammatory and neuroprotective in multiple sclerosis where demyelination and neurodegeneration are prominent. This two-fold role shows that it is a therapeutic target [49], [50], [51].

### **2.3.5 Functional Modulation of S1PR1 in Therapeutics**

S1PR1 functional modulators are pharmacological agents like fingolimod. Initially, these drugs stimulate the receptor but with extended exposure, the receptor undergoes internalization and degradation, which essentially suppresses S1PR1 signalling.

This results in:

- Reduced lymphocyte circulation
- Decreased CNS infiltration
- Suppression of inflammatory responses

Targeting of S1PR1 is selective which helps to improve therapeutic effects and reduce adverse effects caused by non-specific receptor modulation. Such specificity renders S1PR1 a central target of the development of novel MS therapies[52].

## ***2.4 Current Therapeutic Strategies Targeting S1PR1***

The treatment of multiple sclerosis has witnessed startling transformations in that its treatment is not anymore founded on general immunosuppression but it focuses more on the immune pathways. One of the most important developments is the control of lymphocyte movement by means of S1PR1 signalling. Instead of suppressing the immune system of the whole body, the technique selectively changes the migration of immune cells, therefore reducing the inflammation in the CNS. These specific strategies have enhanced the management of diseases by matching treatment with the biological processes [53].

The approval of fingolimod (FTY720) as the first oral S1PR modulator in the treatment of relapsing multiple sclerosis was a significant change in the paradigm of injectable to oral treatment options [54]. Its launch enhanced patient compliance and made S1PR1 a critical drug target in the management of MS [55].

#### 2.4.1 Mechanism of Action

Fingolimod is a prodrug which is a structural analog of sphingosine. Once administered it is phosphorylated by sphingosine kinase-2 to fingolimod-phosphate, the bioactive molecule [56]. First, fingolimod-phosphate attaches itself to S1PR1 and stimulates the receptor. Prolonged exposure, however, causes the receptors to be internalized and degraded, and this will cause functional antagonism. This decreases the availability of receptors on the cell surface, and eventually inhibits S1PR1-mediated signalling.

As a consequence:

- The capacity of lymphocytes to detect S1P gradients is lost.
- T and B cells are prevented from leaving lymph nodes.

- Circulating autoreactive lymphocytes are significantly reduced

This helps to avoid the immune cells entering the central nervous system and minimize inflammation and demyelination [57], [58].

Further, fingolimod is capable of penetrating the blood-brain barrier and acting on CNS cells including astrocytes and oligodendrocytes, which indicates that it may have neuroprotective properties other than immune modulators [59].

#### 2.4.2 Clinical Benefits

Fingolimod has demonstrated strong efficacy in both clinical trials and real-world studies.

- **Reduction in relapse rate:**  
In relapsing-remitting multiple sclerosis, fingolimod is a powerful inhibitor of the annual relapse rate, indicating the best possible suppression of inflammatory processes.
- **Slowing disease progression:**  
There is a correlation between long-term treatment and delayed disability progression and secondary progressive MS transition..
- **Decrease in MRI lesion activity:**  
Treatment results in fewer gadolinium-enhancing lesions and fewer new or growing T2 lesions, both of which point to less CNS inflammation.

- **Improved patient compliance:**  
Oral administration improves adherence compared to injectable therapies.
- **Potential neuroprotective effects:**  
There is an increasing body of evidence that fingolimod can help preserve the survival of neurons, but this needs to be further investigated to determine its neuroprotective effects in the long-term.

### **2.4.3 Pharmacokinetic and Pharmacodynamic Considerations**

Fingolimod exhibits favourable pharmacokinetic properties, including:

- Elevated oral bioavailability
- Extended half-life permitting once-daily administration
- Long half-life allowing once-daily dosing
- Wide tissue distribution, including CNS penetration

Nevertheless, its reliance on in vivo phosphorylation adds randomness to drug activation, which can affect the response to treatment in individuals.

### **2.4.4 Limitations and Adverse Effects**

Despite its effectiveness, fingolimod is associated with several limitations:

#### **Cardiovascular Complications**

- Bradycardia
- Atrioventricular conduction delays
- Hypertension with prolonged use

These effects are linked to non-selective interaction with other S1PR subtypes, particularly S1PR3.

#### **Macular Edema**

The retina may be affected by fluid build-up, which may lead to visual impairment, and it is necessary to monitor it with ophthalmologic care on a regular basis.

#### **Increased Risk of Infections**

Reduced lymphocyte circulation increases susceptibility to viral and opportunistic infections.

#### **Hepatic and Pulmonary Effects**

Some patients have been noted to have elevated liver enzymes and mild changes in lung functions.

#### **Metabolic Activation Requirement**

Fingolimod requires phosphorylation for activation, which:

- Introduces variability in efficacy
- Delays onset of action

#### **Lack of Receptor Selectivity**

Fingolimod binds multiple S1PR subtypes (S1PR1, 3, 4, 5), contributing to adverse effects and limiting specificity [26]–[29].

### **2.4.5 Emergence of Second-Generation S1PR Modulators**

Fingolimod's drawbacks have led to the development of safer and more selective second-generation S1PR modulators.

Examples include:

- **Siponimod:** Targets S1PR1 and S1PR5; effective in secondary progressive MS
- **Ozanimod:** Improved cardiovascular safety profile
- **Ponesimod:** Highly selective S1PR1 modulator with shorter half-life

These newer agents offer:

- Reduced off-target effects
- Improved tolerability
- Better pharmacokinetic control

However, challenges such as long-term safety, cost, and variability in patient response remain.

## ***2.5 Advances in Small-Molecule S1PR1 Modulators***

The effectiveness of the first-generation S1PR modulators like fingolimod showed that S1PR1 is a valuable therapeutic approach in multiple sclerosis. Nevertheless, shortcomings such as the inability to selectively bind the receptors, cardiovascular side effects, and the need to activate the drug metabolism resulted in the creation of second-generation agents with a better specificity and safety profile [60].

One goal of designing these newer compounds is to specifically inhibit S1PR1 and not other receptor subtypes including S1PR2 and S1PR3, which have adverse effects. Siponimod, ozanimod, and ponesimod are better receptor selective and have better tolerability profiles [61], [62].

### **2.5.1 Evolution from First- to Second-Generation Modulators**

The first-generation S1PR modulator fingolimod is able to interact with several receptor subtypes (S1PR1, 3, 4 and 5) leading to both therapeutic and undesirable effects. Second-generation modulators on the other hand have been optimally designed to be structurally:

- Improve receptor subtype specificity
- Reduce off-target interactions
- Enhance pharmacokinetic predictability

This evolution reflects a shift toward precision medicine, where therapies are designed to target specific disease pathways while minimizing systemic toxicity.

### **2.5.2 Improved Selectivity**

Drug development has been a major target of S1PR1. Second-generation modulators are highly affinity to S1PR1 and in certain instances, S1PR5, but not S1PR3-related side effects.

- **Siponimod:** Selectively targets S1PR1 and S1PR5
- **Ozanimod:** High selectivity for S1PR1 and S1PR5
- **Ponesimod:** Highly selective for S1PR1

This improved selectivity leads to:

- Reduced cardiovascular complications
- Lower incidence of bradycardia
- Decreased pulmonary and vascular side effects

Although the safety is improved, targeted lymphocyte trafficking modulation is essential to maintain the therapeutic efficacy level.

### **2.5.3 Pharmacological Advantages**

Second-generation S1PR modulators offer several pharmacological improvements:

#### **Enhanced Safety Profiles**

Selective receptor targeting reduces off-target effects, improving long-term tolerability.

#### **Reduced Cardiovascular Risk**

Limited interaction with S1PR3 minimizes cardiac side effects.

#### **Improved Pharmacokinetics**

- Shorter and more predictable half-lives
- Reduced tissue accumulation
- Faster onset and reversibility

#### **No Requirement for Metabolic Activation**

Unlike fingolimod, some newer agents do not require phosphorylation, leading to:

- More consistent drug response
- Reduced inter-individual variability
- Faster therapeutic onset

#### **Improved CNS Penetration**

Optimized molecular properties improve blood brain barrier permeability which may have better neuroprotective effects.

### **2.5.4 Comparative Clinical Outcomes**

Clinical studies indicate that second-generation modulators:

- Reduce relapse rates
- Decrease MRI lesion activity
- Improve overall disease control

Siponimod was shown to be effective in secondary progressive multiple sclerosis and ozanimod is better tolerated than first-generation agents.

### **2.5.5 Remaining Challenges**

Despite advancements, several challenges persist:

#### **Long-Term Safety Concerns**

Chronic immune modulation may increase susceptibility to infections and other complications.

#### **Incomplete Receptor Specificity**

Residual off-target effects may still contribute to adverse reactions.

#### **Variable Patient Response**

Genetic, metabolic, and disease progression differences impact the results of treatment.

#### **Resistance and Adaptation**

Long-term receptor modulation may alter immune responses, reducing drug efficacy.

#### **Cost and Accessibility**

High treatment costs limit widespread availability despite therapeutic benefits.

### **2.5.6 Importance in Drug Development**

The development of S1PR modulators highlights key principles in modern pharmacology:

- Target-specific drug design
- Minimization of off-target effects
- Optimization of efficacy–safety balance

These principles are still guiding the future treatment approach to MS and other autoimmune diseases.

## ***2.6 Remyelination and Neuroprotective Mechanisms***

In multiple sclerosis, remyelination is a vital process of repair which entails the replacement of the myelin sheaths in damaged axons. Although this is a natural process that happens in the initial stages, it is inefficient in the later stages of the disease causing permanent neurological damage.

### **2.6.1 Mechanism of Remyelination**

Oligodendrocyte precursor cells (OPCs) are the main mediators of remyelination. These cells occur after demyelination:

- Proliferate in response to injury
- Migrate to lesion sites
- Develop into mature oligodendrocytes
- Create fresh myelin sheaths to encase axons.

However, this process is impaired in chronic MS due to:

- Persistent inflammation
- Accumulation of myelin debris
- Inhibitory extracellular matrix molecules
- Reduced differentiation of OPCs

### **2.6.2 Neuroprotective Mechanisms**

Neuroprotection is essential in maintaining neuronal integrity and functioning. The major mechanism of protection is:

- Maintenance of mitochondrial function
- Regulation of intracellular calcium
- Prevention of excitotoxicity
- Reduction of oxidative stress

S1P signalling can help in neuronal survival by promoting intracellular pathways that alleviate cellular stress and apoptosis.

### **2.6.3 Role in MS Treatment**

MS treatments should be effective and target both inflammation and neurodegeneration. Long term management of the disease involves enhancing remyelination and protecting neurons. The main focus of current research is on strategies aimed at survival and differentiation of OPC.

### **2.6.4 Link to Current Research**

New studies indicate that S1PR1 modulation could play a role in immunosuppression and neurorepair. Computational methods of drug discovery have also generated molecules that can act on S1PR1 and which have the potential of having dual action in the treatment of inflammation and regeneration.

## ***2.7 How S1PR1 Binds and Holds Together***

Located in the GPCR family, S1PR1 processes signals of sphingosine-1-phosphate. Since it influences cellular reactions, understanding its folding and its binding to molecules is of great importance in constructing targeted medicines. It is small in size but powerful in its impact on drug development - its shape informs its purpose.

### **2.7.1 How S1PR1 Is Structurally Arranged**

S1PR1 exhibits the typical GPCR architecture, consisting of:

- There are seven transmembrane  $\alpha$ -helices
- Extracellular loops that aid in the identification of ligands
- G protein coupling intracellular domains

Buried within the structure lies a water-repelling cavity, shaped to fit molecules resembling fats - sphingosine-1-phosphate among them, along with similar compounds.

### **2.7.2 Ligand–Receptor Interaction Mechanism**

Ligand attachment to S1PR1 relies on multiple interaction forms:

- Water-avoiding contacts occur at membrane-spanning amino acids
- Hydrogen bonds that stabilize ligand orientation
- Electrostatic interactions between charged groups

When the receptor undergoes shape shifts as a result of these encounters, activation of intracellular signalling pathways occurs. Although it may not be very noticeable, these structural adaptations play a very crucial role in relaying signals across the cell membrane.

### **2.7.3 Binding Specificity and Selectivity**

To minimize undesirable interactions, it is possible to target S1PR1 in isolation as other subtypes of S1PR (S1PR2 -S1PR5) have side effects. Due to slight variations in the shape of the binding site, scientists exploit these minute differences in the making of precise compounds. Each receptor in spite of its similar structure reacts differently to customized molecules.

### **2.7.4 Role in Creating Medications**

Detailed knowledge of receptor structure enables:

- Identification of key amino acid residues involved in binding
- Optimization of ligand affinity and selectivity
- Rational design of novel therapeutic compounds

### **2.7.5 Link to Current Research**

The binding of the selected compounds to S1PR1 is investigated in this work using molecular docking. By these associations scientists have an opportunity to know about which substances are the best bonding agents. Some of them are more fitting due to their structural fit. Such trends are understood and help in the development of new medicines. What matters is stability, and agreement of parts as they collide.

## ***2.8 Using computers to find new medicines***

The beginning with computers has transformed the way new medicines are discovered by scientists it is now cheaper and quicker to view potential treatments. Due to this change, digital tools are now invaluable in addressing challenging diseases such as multiple sclerosis [66].

### **2.8.1 Molecular Docking and Structure Based Drug Design**

First of all, molecular docking - it is a computer technique which determines how small molecules bind to selected proteins. Direction and strength of the connection are indicated in this process. The next step is based on the simulation of interactions at the atomic level [65].

- Placement of ligands into the binding site
- Interaction energy assessment
- Prediction of binding poses

Docking provides insights into:

- Binding strength
- Interaction patterns
- Stability of protein–ligand complexes

Beginning with protein shapes in three-dimensional shapes, scientists design compounds, which are supposed to bind better. Due to the fact that structural details determine decisions, molecular alterations are made in accordance with definite spatial hints [65].

### **2.8.2 Virtual Screening and Ligand Optimization**

Beginning with digital models, virtual screening of huge sets of chemical compounds is done to identify potential medicines. Researchers save time because it involves computer simulations as opposed to using lab-only methods [66].

- Ligand-driven methods rely on information from previously identified active molecules
- Structure-based (based on target protein structure)

Selected compounds are further optimized to improve:

- Binding affinity
- Selectivity
- Pharmacokinetic properties

### **2.8.3 ADME and Drug Likeness Prediction**

For judging how well a drug might work, looking at ADME - how it gets absorbed, spreads through the body, changes chemically, and leaves - is crucial. Important factors to consider are:

- Lipophilicity (LogP)
- Molecular weight
- Hydrogen bond donors/acceptors
- Bioavailability

Often applied in early drug screening, Lipinski's Rule of Five helps identify molecules with potential absorption issues [67].

### **2.8.4 Limits of Computer Calculations**

Even so, these methods come with constraints:

- Approximate scoring functions
- Static representation of proteins
- Lack of biological complexity

For this reason, experiments are needed to confirm what computations show [68].

### **2.8.5 Present Study Link**

The first part of this work starts by describing molecule shape, in which docking simulations are applied, together with absorption predictions, to discover new S1PR1 regulators. The combination of these methods enables scientists to not only establish the strength with which these substances bind but also approximate how the body handles the substances. They are not perfect, but help to filter candidates at an earlier stage [65–67].

## ***2.9 What We Don't Know and Why This Study Matters***

Although the treatment of MS has been improved, it still has some issues. As much as the therapeutic interventions including fingolimod and enhanced versions result in better outcomes, they have their share of faults - side effects manifest with a high frequency. Their effect on receptors is imprecise and they lead to various responses in individuals. As a result of such gaps, more differences in the responses emerge than expected among patients [51,52].

### **2.9.1 Identified Research Gaps**

- Lack of highly selective S1PR1 modulators
- Adverse effects associated with existing therapies
- Limited exploration of novel small-molecule candidates
- Need for improved pharmacokinetic and safety profiles

### **2.9.2 Need for New Treatment Methods**

- Safer and more selective drugs
- Compounds with improved bioavailability
- Therapies that address both immune and neurodegenerative aspects

### **2.9.3 How Computers Help Solve Problems**

Computational drug discovery provides an efficient platform for:

- Screening large compound libraries
- Predicting binding interactions
- Evaluating pharmacokinetic properties [65–67]

#### **2.9.4 Study Rationale**

One goal of this work is to find new small molecules that affect S1PR1, using computer-based approaches. To reach it, researchers combine molecular docking with ADME evaluation. This path allows a closer look at potential compounds without relying on broad assumptions.

- Identify compounds with high binding affinity
- Evaluate their drug-likeness properties
- Propose potential candidates for further development [65–68]

### **3. METHODOLOGY**

#### ***3.1 Retrieval of S1PR1 Protein Structure***

From the Protein Data Bank - a huge collection of known biological structures - came the 3D shape of S1PR1, the protein under investigation. Because docking results rely heavily on how well the protein's form is defined, picking a reliable version mattered right at the start. Though many models exist, only one fit the needed precision for these calculations.

A human S1PR1 structure is resolved by either X-ray crystallography or cryo-electron microscopy formed the starting point. Since finer details emerge at higher resolutions, such data allows clearer views of where atoms sit. That clarity matters when mapping out the pocket that binds molecules. With precision in mind, just those entries reaching 3.0 Å resolution - or sharper - moved forward into evaluation.

Of importance also was the identification of a ligand embedded right into the shape of the protein. Since it is the binding site, researchers are able to observe precisely the manner in which molecules occupy it. With that molecule in place, scientists make their boundaries around the point where new ones are to be placed. It challenges the consistency of computer guesses with real-world behaviour, so that findings are not rooted in real biology.

- To crown it all, protein shapes were favoured that were on display.
- Clearly defined places where molecules are bound, each part is immediately at the point of work.
- Full chain information, with structural integrity.

Only a few small cleavages in the structure, particularly around the molecule insertion point.

A file was downloaded in .pdb format - compressed with atom locations, part names, string labels, inter-part connections. The tools creating small shapes often assume this form, which simply fits into steps preparing proteins.

Simply to be in a position to observe where the molecule fits, it is better to check the structure initially to denote opening it in a viewer. Everything can go wrong since now something looks improper. The timely identification of issues increases predictability of future outcomes. The tying spot should have been tidy, no knots or waste. That way, the subsequent steps are more likely to be comprehensible.

This technique yielded a stable protein shape. That one had become the criterion, in ascertaining the fit of molecules with each other. It also enabled the scientists to explore the places of compounds attachment. Next binding strength was determined. There was specificity in these tests. Form guided everything of the attractions of molecules.

### ***3.2 Preparation of Target Protein***

The starting point was the raw protein file, which was refined through each step to the structure to achieve better docking results. The need of these pieces was because the entries of the Protein Data Bank are likely to have extras like water molecules or metal ions. A series of changes helped to create a validated variant of the protein that was able to be used in testing interactions. Only at that time the model could be applied without any unwanted interference.

The protein preparation was done by sending Auto Dock Tools out in the periphery of the working space. In Pyrx, visualization was given and a clear view of the structure was provided. Every cut was by the snipe of a pencil, by purgatory until something began to move. Having such programs running simultaneously kept adjustments accurate. The entire arrangement ensured that nothing passed a close scrutiny before docking.

#### **Removal of Non-Essential Molecules**

Out came every part that wasn't needed from the downloaded setup first. Things like extra scripts, unused files, filler folders - gone

- Crystallographic water molecules
- Bound ions
- Co-crystallized ligands

In the majority of cases, the water molecules are omitted in the course of docking work since they can complicate things. Although such molecules might assist in connections, their elimination facilitates the setup. The same with ligands already in situ - away they go. Nuclear clearing allows other compounds to enter the active site without complications.

#### **Addition of Hydrogen Atoms**

The majority of proteins available in PDB files are not provided with explicit hydrogen information, particularly polar bond - major contributors to hydrogen bonds. So, these missing polar hydrogens were inserted into the model where they were required.

This step is essential because:

- Hydrogen bonds are significant when molecules are sticking together. These connections aid in the formation of the relationships between the substances. In their absence, gluing

one piece to another would not be the same. They silently tend to show the way parts their counterparts.

- Correct states of protonation affect accuracy of interaction.
- It enhances accuracy of docking forecasts.

### **Charge Assignment**

Beginning with the protein structure, Kollman partial charges were applied using Auto Dock Tools to determine the electrical interaction of the protein structure with ligands. And the absence of these values would make the simulation of attraction or repulsion imprecise.

Computing binding energies Modelling the electrostatic repulsive and attractive forces Ensuring natural behaviour at the docking point.  
energy loss and shape enhancement.

Although experimental data are used in the creation of PDB models, minor problems such as overlapping atoms or strained bonds may still be present. Where necessary, minor modifications were done to enhance geometry. The refinements involved only problematic areas and did not change the overall structure. Each change was guided by precision and was minimally invasive.

This process supports the following outcomes

- Relieve steric hindrance
- Stabilize local geometry
- Improve the overall quality of the receptor structure

Great effort went into limiting changes to the protein, ensuring its natural shape - particularly how the binding site is structured - stayed unchanged.

### ***3.3 Selecting and Finding Ligands***

Among early stages in computer-aided drug design, pinpointing proper ligands is at the heart of things - as the choice of compounds determines the extent to which the results of docking can be trusted. The choice of these molecules in this case was driven by rational filtering; structural similarity was used to pick some of them, biological activity and similarity with existing medicines were used to pick others - all in the quest to identify potential agents at the S1PR1 receptor.

The approach using the similarity of the molecules started with the known structure of fingolimod (FTY720), a known S1PR1 modulator. When compounds contained common core structures or functional centers, they rose in priority - structural similarity often portends bioactivity similarity. Owing to shape and group positioning that affects the binding of molecules, the choices were determined by these properties. Close architecture does not necessarily imply similar functionality, but it is frequently the case. Therefore, it focused on parallel pattern of building.

### **Find Possible Compounds**

Beginning with PubChem, scientists identified potential ligand hits using the large repository of molecular data and associated bioactivity information available in PubChem. In order to identify

these, queries were based on certain terms typed in the system. In that, similar compounds were identified using structural similarity and reported interactions.

- Fingolimod-related structural resemblance searches
- Keyword-based searches related to S1PR1 modulators
- Filtering options to narrow down relevant small molecules

Out of that first check came several possible compounds, now lined up for closer look.

### Selecting Compounds by How They Act Like Drugs

Beginning with simple characteristics associated with absorption, every compound was analyzed by a set of proven standards. Rules such as these may not be the best predictors but they tend to result in the identification of viable candidates at an early stage. In such a system, properties matching standard thresholds - e.g., molecular weight or solubility - were propelled forward. Others got through because of borderline values; some others were exceptional because they passed more than one marker. Making it this far did not ensure success but it lessened apparent dangers associated with behaviour within the body.

- Appropriate molecular weight
- Balanced lipophilicity
- Acceptable number of hydrogen bond donors and acceptors

Compounds with poor absorption were put under early review. By eliminating such early, there is an opportunity to discover viable treatments in later life. Structural Feature.

The occurrence of certain structural features known to mediate S1PR1 binding, such as, was given special consideration:

- **Hydrophobic chains:**  
These aid in interaction with the lipophilic binding pocket of S1PR1, leading to an increase in binding stability.
- **Polar functional groups:**  
Functional groups, including hydroxyl, amine or phosphate-like groups, promote hydrogen bonding and electrostatic interactions with functional groups of key amino acid residues.
- **Amphipathic character:**  
It was found desirable to include molecules with hydrophobic and hydrophilic regions, since they would imitate the structural behaviour of endogenous ligands and known modulators.

### Ligand Retrieval and File Format

Among the selected molecules, one of them was downloaded through PubChem in the .sdf format - a format that contains structural information. The given extension contains data on atom positions as well as bond configurations. Each record contained coordinates and molecular properties that can be further analysed. The data package provided the 2D and 3D representations as standard output.

Three-dimensional structural coordinates

- Bond connectivity information
- Chemical property data

- Importantly, the .sdf format is a good starting point in most computational projects since it can be easily converted into the forms needed to be docked. Its wide usage facilitates the easy ligand preparation before simulations.

### **Preliminary Screening and Selection**

Among all the tested substances, some of the molecules were propagated, having satisfied certain conditions. There are those candidates who stood out due to their suitability to certain requirements. Some few were picked after preliminary findings recorded encouraging results. After examination, specific structures gained more ground as a result of favourable interactions. It was only those with appropriate binding behaviour that survived the first stage.

- Connection to S1PR1 modulators based on molecular framework
- Chemical stability
- Processing readiness for subsequent computational tasks

After selection, the ligands were processed and refined by subsequent steps and then applied in molecular docking.

### **Ligand Choice Matters**

Choosing ligands with precision means that:

- Docking results are biologically meaningful
- Interactions that bind matter when it comes to hitting the intended receptor
- Identified compounds have potential for further development

The work done here is used to build up computational work, either in terms of docking, molecular interactions, or drug behaviour. This stage is critical in later stages, in that it unobtrusively drives the outcomes.

### ***3.4 Ligand Preparation***

After the selection and collection of candidates, their structures had to be adjusted and docking could only occur. This step is important - errors here can cause changes in the way molecules will fit in the future.

Beginning with molecule setup Open Babel was used to do initial formatting and then structures were passed to Auto Dock Tools. Each program assumes its role as the next step without encroachment. They are independent but when used together they conform to typical patterns found in digital screening pipelines. Such commonly used tools as these frequently go hand in hand when compounds are being prepared to be studied using simulations.

### **File Format Conversion**

PubChem database ligands were in the form of .sdf files - perfect to store molecular information, but incapable of directly inserting into docking software. This type is not

readied to deal with simulation workflows although it was designed to deal with chemistry data.

With Open Babel, conversion into .pdb format became possible

- Compatibility with molecular visualization tools
- Further structural editing and preparation
- Integration into docking workflows

Standardization of every ligand structure happened here, preparing them for what followed next.

### **Geometry Optimization**

Beginning with modified ligand shapes, energy-based refinement ensued to achieve low-stress shapes. In this way, interatomic distances change slightly and angular relations change - decreasing tension throughout the structure.

Energy minimization helps to:

- Remove unfavourable steric interactions
- Stabilize molecular geometry
- Improve the accuracy of docking predictions

As optimized structures are more realistic biological shapes, the evaluation of interactions becomes more reliable. It is these shapes that molecules actually assume in life. Their accuracy increases when the models resemble the natural conditions. The inferences about binding are more powerful when the configurations resemble actual behaviour. Improved consistency with biology will imply reduced errors in contacts predictions.

### **Addition of Hydrogen Atoms**

Purposely, some hydrogen atoms - that are normally missing or omitted in structure files - were replaced in every ligand. That includes both polar and non-polar ones.

The addition of hydrogens is important because:

- Atoms of hydrogen take part in essential connections, including those known as hydrogen bonds
- With correct valency and bonding setups confirmed
- Accuracy in electrostatic computations increases due to it

### **Charge Calculation**

To model accurately electrostatic forces between ligands and proteins, partial charges based on Gasteiger were used - each ligand was run through Auto Dock Tools. Automated, the technique is used to ensure uniform distribution of charges which is vital in accurate interaction.

These charges are crucial to:

- Predicting binding affinity
- Simulating intermolecular interactions
- Ensuring realistic docking results

### **Rotatable Bonds Explained**

The ligand should be flexible enough in the process of docking since there can be different shapes when the ligand binds. This is why all the bonds of compounds were found to be rotatable.

This step allows:

- Exploration of different conformations during docking
- Identification of the most stable binding pose
- A tighter fit inside the receptor's binding site improves interaction. Placement is slightly changed and contact is improved. Such a modification contributes to the better alignment. Shape changes help stabilize the connection. Improved positioning follows naturally from these adjustments

Preserving rigid functional groups remained a priority during assignment of rotatable bonds. While setting up molecular connections, correct placement guided each decision. Not every bond allowed rotation - some stayed fixed by design. Attention focused on maintaining structural accuracy throughout the process. Where flexibility mattered, adjustments followed clear chemical rules. Integrity of key components shaped how rotations were defined. Correctness came from balancing movement with stability.

### **Final Conversion to Docking Format**

Once preparations finished, the ligands changed into .pdbqt form - needed only for Auto Dock-style docking runs. This format step came last, following every earlier task. Software of that type cannot process anything else. Conversion made sure everything ran without glitches later on.

The .pdbqt file includes:

- Atomic coordinates
- Assigned partial charges
- Defined atom types
- Information on rotatable bonds

With this version locked in, docking software works without hiccups while modelling how molecules bind to proteins precisely. Though built for stability, its real strength shows when predicting complex biological fits reliably.

### ***3.5 Molecular Docking Procedure***

Starting with molecular docking, predictions emerged about how tightly certain molecules might stick to S1PR1 and where they would connect. Since this process unveils information regarding the fit within the working region of the protein, it carries some weight in the analysis. The execution of these tests was based on AutoDock Vina - a software that is characterized by fast execution and does not compromise performance in terms of score estimation.

#### **Docking Setup**

Before running, the ready protein and ligand models entered the docking setup. AutoDock Vina input consisted of the receptor, which is saved in the form of.pdbqt, and correspondingly formatted ligand files. Though formatted separately, each piece fit the software's requirements. Each file type - protein and small molecule - arrived prepped for interaction analysis. Running began only once both components were recognized by the system.

The location of the grid box is a key factor in docking and determines the location of ligand interaction to be assessed over the protein surface. Located strategically around familiar points of contact, it surrounds the active site of S1PR1 - often guided by prior structural clues such as bound molecules or critical amino acids involved in recognition.

Among the values set were:

- Position of the middle point along x, y, z axes:
- These values are centered around the binding pocket, and they indicate where the search starts. Their location is the result of the features of that particular area.
- The extent of the grid is measured in three perpendicular directions. The elements are aligned in dimensions along each axis. Rules of spacing are applicable irrespective of position. Total volume capacity is based on values obtained. Direction-specific lengths have the effect of affecting structural behavior under load.
- A marginally bigger size was necessary to be sure to include the active site, but omit irrelevant parts. This change reduced the processing power that was wasted due to a concentrated culmination in areas of necessity. Efficiency increased because additional areas remained beyond the border.

The grid is a good place to start as it only creates the best docking and also consumes less computing time as only the areas that are likely to be of interest are visited. This may be a humble gesture, but it can direct the entire process by putting the efforts where they matter.

### **Docking Parameters**

For consistent capture of ligand shapes, docking settings were carefully chosen:

#### **Exhaustiveness:**

- Searching more deeply depends on this setting. The greater the number, the better the chance to find the best fit for binding - yet each step adds time to processing. Reaching a balance matters when running these calculations.
- How many poses appear in the result:
- In each case of a ligand, a number of binding shapes were obtained - all of which provide how an orientation could change during interactions. Various configurations were observed, indicating the possible different positions of the molecules during attachment. These different forms allowed the observation of contrasts in positioning. Rather than a single pose, there were various compositions that appeared. Both structures provided an insight into other possibilities of contact.

#### **Scoring function:**

- Predictions of binding strengths based on the standard scoring of AutoDock Vina, which takes into account the attractive forces between molecules, such as hydrogen bonds as well as hydrophobic touchpoints or electrostatic pulls. Although simplistic in

nature, the methodology is able to represent important forces that can determine the degree of sticking together of molecules in the normal circumstances.

These settings were built jointly, maintaining speed and accuracy in step in docking runs.

### **Docking Execution**

Docking runs were performed into the given region of S1PR1 using AutoDock Vina, with each ligand being placed individually. The individual simulations tested various positions in the active site, with the scoring functions used to determine fit.

Each ligand produced a result that contained:

- Energy of interaction in kilocalories per mole.
- These numbers manifest themselves in binding strength. The lower they are the more strongly they are attached.

### **Multiple binding poses:**

- Starting from varied angles, multiple shapes emerged, each showing how the molecule might sit inside the pocket. One after another, these arrangements revealed shifts in placement and direction across the space where binding occurs.

### **Interaction coordinates:**

- Position details of the ligand in relation to receptor amino acids are clearly mapped. The layout shows how close each residue sits beside the binding molecule. Where the ligand rests depend on specific contact points along the protein surface. Nearby chemical groups influence placement through directional interactions. Mapping reveals alignment patterns that shift across different conformations.

### **Selecting the Best Docking Pose**

Out of the docking outcomes produced, top-ranked configurations for every ligand emerged through careful evaluation using multiple indicators together. Selection leaned on scoring values alongside spatial fit and interaction patterns observed across runs. Preferred poses showed consistent alignment with favourable energy levels seen during analysis. Each choice reflected a balance between stability signs and repeatable positioning noted in outputs

- Lowest binding energy:
- Favourable energy levels marked the pose showing the lowest binding affinity.

### **Favourable interaction pattern:**

- Of the shapes that could be obtained, ones that could make clear hydrogen bonds or be snugly packed around essential components of the active site were of particular interest. There were those that were paired by water bridges, and others that perfectly matched surface characteristics. Stability was significantly enhanced where molecules were bound in place with amino acids that were important. Fits with non-polar surfaces tended to add strength without charge interactions. When contact points were aligned accurately positioning became the most important thing.
- Placed in the right location within the cavity of binding.
- Proper fitting in the binding pocket is important - when misaligned this creates problems. Form is incompatible or it is placed in strange positions. Avoidance of straining by proper

orientation. The positioning should be in accordance with the natural movement patterns. Form is met by space and stability ensues.

**Matching established patterns of interaction:**

- When possible, researchers matched the chosen pose against established S1PR1 modulators, checking for alignment with real-world activity. Though less obvious at first glance, similarity to documented compounds helped confirm meaningful results. In cases where reference points existed, consistency with prior data shaped confidence in the selection. Only those poses mirroring recognized patterns moved forward into further analysis. Without such comparison, uncertainty would have grown quickly behind the scenes.

### ***3.6 Binding Interaction Analysis***

After molecular docking, examination of the protein–ligand complexes revealed specifics about how tightly and in what manner the chosen ligands bind to the S1PR1 receptor. Understanding these details helps clarify which amino acids play a central role during binding, along with the forces that stabilize the interaction.

From start to finish, PyRx paired with Discovery Studio Visualizer guided how structures were viewed and explored. Through these platforms, close attention was paid to where molecules settled, how they connected, and their positioning inside target regions. What stood out was the clarity in seeing ligand behaviour once docked - revealed step by step through visual mapping.

#### **Analysis of Binding Interactions**

From every docked complex, a close look revealed which forces helped hold molecules together. Hydrogen bonds, hydrophobic contacts, electrostatic attractions, van der Waals forces, and pi stacking took part in stabilization. With each structure, patterns emerged showing how these connections varied in strength and position. Though subtle, shifts in distance or angle sometimes changed the dominant force at play. Where one interaction weakened, another often compensated nearby

#### **Hydrogen Bonding**

Among key factors shaping how tightly molecules stick, hydrogen bonds stand out. When parts of a molecule offer hydrogen atoms, others nearby can pull them gently into place. The power depends upon the spacing, the amount, and the location. It is not the presence but the proximity and alignment that matters. The measurements of these links are taken to produce patterns.

#### **Hydrophobic Interactions**

The forces that avoid water aid in keeping the ligand stationary within the greasy regions of the receptor site. Due to the clustering effects of these segments, the non-soluble parts of the molecule that are not aqueous connect with the corresponding regions in the protein structure.

#### **$\pi$ – $\pi$ Stacking Interactions**

In the case of aromatic rings of the ligands, their attraction with amino acids such as phenylalanine, tyrosine, or tryptophan was studied. These groups act in the same direction and the binding strength becomes high, and the internal structure is stabilized within the target one.

#### **Electrostatic Interactions**

To understand how charged opposites are attracted, it is useful to consider what goes on with parts of a molecule attaching to charged regions on a protein surface due to static forces such as salt

bridges or aligned dipoles. To understand these attractions, one is required to follow where positive collides with negative without the need to have covalent bonds to hold things together. The presence of these connections is because of differences in the distribution of the electrons among the atoms involved. What matters most is the spatial match between donor and acceptor sites along with their relative polarity. Forces driven by charge show up clearly when molecules approach one another under stable conditions.

### **Key Binding Residues Identified**

Among those lining the S1PR1 binding site, certain amino acids stand out due to their role in engaging the ligand. Their presence proves crucial for:

- Stabilizing the ligand within the active site
- Determining binding specificity
- Influencing receptor activation or inhibition

Patterns of interaction seen during analysis matched against documented contact points from proven S1PR1 modulators helped confirm the docking outcomes. Though validation relied on prior data, alignment with existing residue information supported accuracy. Where connections formed in simulations, they lined up closely with those previously identified. These overlaps arose not by chance but through consistent spatial and chemical compatibility. Confirmation emerged gradually as each binding site detail fell into place alongside earlier findings.

### **Interaction Maps Generated**

Maps showing interactions in two and three dimensions came from work inside Discovery Studio Visualizer. Built this way, they revealed details clearly about:

- Binding orientation of ligands
- Interaction kinds that emerge
- Residues involved in binding

Visual tools help make sense of docking outcomes, offering a straightforward way to share results. These displays bring clarity while organizing complex data into something easier to follow.

## ***3.7 ADME and Drug Likeness Evaluation***

While binding strength matters, how a molecule moves through the body also shapes its potential as a medicine. To explore this, computer-based analysis looked at absorption, distribution, metabolism, and excretion traits. This step helped judge whether the chosen compounds act like realistic drugs. Instead of relying only on interaction data, their overall journey in biological systems was examined.

Using SwissADME, an online tool, the evaluation examined key traits like solubility and absorption through trusted computational methods. Though web-based, its algorithms draw from widely tested frameworks for forecasting drug behaviour. This approach allows insight into how compounds might perform inside the body without lab testing. Performance indicators such as molecular weight or lipophilicity emerge directly from structure inputs. Because predictions rely on pattern recognition, results align closely with observed trends in real molecules.

### **Evaluation of Physicochemical Properties**

Analysis of crucial molecular traits aimed to assess if chosen ligands show features typical of drugs taken by mouth

- **Molecular Weight:**

Often, substances of medium size work best because very big ones tend to struggle getting absorbed or moving through barriers.

- **Lipophilicity (LogP):**

Because lipophilicity affects how well compounds cross membranes and dissolve, its role matters greatly. A balanced LogP helps maintain both water attraction and fat compatibility - key for proper uptake into the body. What happens next depends on that equilibrium staying intact.

- **Hydrogen Bond Donors and Acceptors:**

- Hydrogen bonding ability defines the dissolution or interaction of molecules with the biological systems. The characteristics which characterize such bonds are that such bonds are readily formed - this tunes behaviour in water and target binding strength.

- Calculated surface area of polar atoms (topological).

- TPSA is commonly disregarded and it is a measure of the possibility of a molecule to cross cell membranes. The lower the values, the more flow into cells is likely to be increased - the same can be said about the brain. A shift towards the lesser figures would suggest the diminution of the challenge in surmounting the impediments like that produced by blood vessels.

## Pharmacokinetic Property Assessment

For a deeper look at how the drug might perform, researchers checked multiple factors tied to absorption, distribution, metabolism, and excretion

- **Water Solubility:**

For a medicine to be absorbed and reach circulation, it must dissolve well. Poor dissolution limits how much enter the bloodstream. Without sufficient breakdown in fluids, effectiveness drops sharply. How easily it mixes with bodily liquids decides its success. Absorption hinges on this physical property above others.

- **Gastrointestinal (GI) Absorption:**

Oral intake of a substance often leads to quick uptake if its GI absorption is high. What matters most is how rapidly the body pulls it into circulation after ingestion. Efficiency shows up clearly in blood concentration levels soon afterward. When digestion releases it fast, measurable effects follow without delay. Speed of entry becomes obvious through consistent patterns seen across studies.

- Permeability of the Blood–Brain Barrier (BBB)

- Beyond its impact on nerve function, Multiple Sclerosis demands treatments capable of reaching the brain - making passage through the blood-brain barrier essential. What works elsewhere in the body may fail here if it cannot traverse this protective layer. Effectiveness hinges not just on molecular design but also on access. Without entry into the central nervous system, even potent agents fall short. The journey across the BBB shapes whether a compound can actually engage the disease.

- **Metabolic Stability (Predicted):**

These compounds - metabolic changes can happen - these changes affect the length of action of a drug. Their behavior during breakdown would help to achieve overall effectiveness.

### **Drug-Likeness Evaluation**

The possibility of the chosen ligands to be used as orally active agents was quantified by Lipinski Rule of Five - a validated criterion that has been associated with oral absorption.

In case where the substance exceeds some limits, it is likely to show more opportunities provided that the substance is not beyond the limits:

- Weight at the molecular level stays under five hundred daltons
- $\text{LogP} \leq 5$
- The maximum number of hydrogen atoms that can be donors is five.
- Bonding locations with ten or fewer hydrogen.

The positive drug-like characteristics were associated with the compounds passing the required criteria.

#### **Extra Screening Checks If Needed**

Additional filters might apply, including:

- Bioavailability score
- Synthetic accessibility
- PAINS (Pan Assay Interference Compounds) alerts

Other factors played a role in sharpening the pool of possible applicants.

### **Selecting Possible Drug Candidates**

An examination of physical characteristics and the way the body takes them in facilitated the elimination of potential ligands. Individuals with good performance in these aspects were given priority.

- Acceptable ADME profiles
- Compliance with drug-likeness rules
- Favourable balance between solubility and permeability

Some showed potential, making them suitable for deeper study.

### **Why ADME Analysis Matters**

ADME analysis is an important process in computer-based drug discovery in that it assists in:  
Get rid of compounds that have bad pharmacokinetic characteristics.

Minimise the chance of late drug failure.

Enhance lead optimization effectiveness.

Both ADME profiling and docking information should be given a starting point in order to have a more complete picture of possible drug candidates. A combination of these techniques provides an insight that each one would not provide individually.

## **4) RESULTS AND DISCUSSION**

#### ***4.1 ADME Analysis and Initial Screening***

Beginning with structural approaches, scientists sought molecules that were similar to fingolimod in shape. SwissSimilarity was one of the tools that were used in order to identify potential matches between existing compounds. The compounds with scores over 0.85 were regarded as good candidates because of their similarity. There are twenty such substances that have been advanced, exhibiting both structure and activity that could be consistent with S1PR1 effects.

Based on the chosen group, compounds proceeded to the analysis of their behavior within the body - SwissADME was in charge of these tests. Each was required to meet a number of requirements to remain in consideration, including brain access and general similarity to known medicines. Whether a compound could cross into the brain and get absorbed through the gut shaped part of the decision process. Often, success depended on traits like BBB penetration and GI uptake after being taken by mouth. Another checkpoint involved Lipinski's five key markers, which hint at whether an oral dose would work well.

Out of the initial group, some were dropped once screened through PAINS and Brenk rules - structural red flags or toxicity concerns being the reason. Those left behind passed every checkpoint without triggering warning signals worth noting. What remained stood apart by showing steady, promising ADME traits across the board. These few emerged with properties aligned well toward possible development as drugs.



This method cut down the pool of potential molecules by focusing early on structural fit and absorption traits, so fewer reached the docking phase yet quality stayed high. Only those matching both shape requirements and body-processing needs moved forward, streamlining what followed without losing key candidates.



#### ***4.2 Visualizing Ligands in Docked Positions***



Looking at the way ligands bind to S1PR1, two-dimensional diagrams were built with BIOVIA Discovery Studio. Through these images, the positioning of each molecule inside the receptor's cavity became more apparent. What stood out was how fully each compound filled the region responsible for activation. From there, specific connections between the ligands and parts of the protein came into view - hydrogen bridges, nonpolar associations, and additional bonding influences. Each contact helped explain why certain molecules held their place more firmly than others.


Among the tested compounds, shifts in how they bind revealed distinct interaction styles, hinting at divergent stabilities. These contrasts brought clarity to molecular arrangements, enriching what scores alone could show. Looking closely helped confirm predictions, strengthening confidence in selecting potential leads.

TABLE 1 : TABULAR REPRESENTATION OF IUPAC NAMES ,2D STRUCTURE AND BINDING AFFINITIES OF INTERACTING LIGANDS


<i>PUBCHEM ID</i>	<i>IUPAC Name</i>	<i>2D Structure</i>	<i>Binding affinity(kj/mol)</i>
107970 (REFERENCE Ligand)	2-amino-2-[2-(4-octylphenyl) ethyl] propane-1,3-diol		-7.3
11779629 (ligand 2)	4-[(1S,2R)-1-hydroxy-2-[[[(2R)-1-phenoxypropan-2-yl] amino] propyl] phenol		-7.4

<i>PUBCHEM ID</i>	<i>IUPAC Name</i>	<i>2D Structure</i>	<i>Binding affinity(kj/mol)</i>
110145611 (ligand3)	[(3Ar,6As)-5-phenylmethoxy-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl]-[4-(2-aminoethyl) phenyl] methanone	 The image shows a 2D chemical structure of a complex molecule. It features a central cyclopentane ring fused to a pyrrolidine ring. Various substituents are attached, including a phenylmethoxy group, a 2-aminoethyl group, and a 4-(2-aminoethyl)phenyl group. The structure is rendered with a light gray background.	-7.6
126442807 (ligand4)	2-[(2R)-4-[[4-(2-phenylethoxy) phenyl] methyl] morpholin-2-yl] ethanamine	 The image shows a 2D chemical structure of a complex molecule. It features a central morpholine ring with a 2-phenylethoxy group and a 4-(2-phenylethoxy)phenyl group. The structure is rendered with a light gray background.	-7.7


<i>PUBCHEM ID</i>	<i>IUPAC Name</i>	<i>2D Structure</i>	<i>Binding affinity(kj/mol)</i>
95895820 (ligand5)	(1R)-1-[1-[[4-(2-aminoethyl) phenyl] methyl] piperidin-4-yl]-2-phenylethanol		-8.1
77050638 (ligand6)	[(1R,3S)-1-amino-3-[(6R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl] cyclopentyl] methanol		-8.8




**Fig.1. Interaction between ligand no.1 2-amino-2-[2-(4-octylphenyl) ethyl] propane-1,3-diol i.e. Reference compound and target S1PR1**




**Fig.2. Interaction between ligand no. 2 4-[(1S,2R)-1-hydroxy-2-[[2-(2R)-1-phenoxypropan-2-yl] amino] propyl] phenol and target S1PR1**




**Fig.3. Interaction between ligand no.3 [(3Ar,6As)-5-phenylmethoxy-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl]-[4-(2-aminoethyl) phenyl] methanone with target S1PR1**



**Fig.4. Interaction between ligand no. 4 2-[(2R)-4-[[4-(2-phenylethoxy) phenyl] methyl] morpholin-2-yl] ethanamine with target S1PR1**



**Fig. 5. Interaction between ligand no.5 (1R)-1-[1-[[4-(2-aminoethyl) phenyl] methyl] piperidin-4-yl]-2-phenylethanol and target S1PR1**



**Fig. 6. Interaction between ligand no. 6 [(1R,3S)-1-amino-3-[(6R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl] cyclopentyl]methanol and target S1PR1**

TABLE 2 : TABULAR REPRESENTATION OF ADME ANALYSIS OF INTERACTING LIGANDS

<i>PUBCHEM ID</i>	<i>BBB Permeant</i>	<i>GI Absorption</i>	<i>Lipinski</i>	<i>Ghose</i>	<i>Log Kp value</i>
107970 (REFERENCE COMPOUND)	Yes	High	Yes	Yes	-5.22
11779629	Yes	High	Yes	Yes	-6.14
110145611	Yes	High	Yes	Yes	-6.47
126442807	Yes	High	Yes	Yes	-6.40
95895820	Yes	High	Yes	Yes	-6.12
77050638	Yes	High	Yes	Yes	-4.46

## 5) CONCLUSION

The molecular docking analysis carried out in this study provided important insights into the binding behaviour of fingolimod and a series of structurally related compounds toward the S1PR1 receptor, a well-established therapeutic target in Multiple Sclerosis. The results indicate that all selected ligands were able to successfully occupy the receptor's binding pocket and form energetically favourable complexes, suggesting that the chosen chemical space is relevant for S1PR1 modulation.

Among the screened molecules, **ligand 6** exhibited the most favourable binding profile, showing the lowest binding energy compared to all other compounds included in the study. This indicates a stronger and more stable interaction with the receptor, which may be attributed to optimal alignment within the binding site and the formation of multiple stabilizing interactions such as hydrogen bonds and hydrophobic contacts. Such a higher binding affinity of this ligand suggests that even subtle structural differences present at the chemical scaffold may significantly alter the receptor interaction.

The remainder of the compounds had binding affinities that were comparable or slightly lower than the reference drug fingolimod. This finding points out a significant feature of drug design based on structure: **structural similarity alone does not guarantee improved biological activity**

**or binding efficiency.** Though the compounds shared a number of similar features with fingolimod, the position shift of functional groups, flexibility of the molecules and geometry of the compounds were likely the causes of the difference in the docking performance.

In any case, the overall binding trends of the entire set of ligands would indicate that the underlying chemical scaffold used in the present study is pre-programmed to bind the S1PR1 receptor. The compounds exhibited some stable binding patterns and interactions patterns that resemble those of known modulators, which can be interpreted as the support of the idea that this scaffold can be a reliable starting point to be further modified.

One of the most interesting discoveries is that there is a similarity in the pattern of interaction between high-performing ligands, and more specifically with key residues being engaged in the binding pocket. This implies that some of the structural features play a key role in effective receptor binding and can be strategically conserved or optimized in subsequent compounds. In this regard, ligand 6 turns out to be a promising lead molecule, as it not only has a higher docking score, but also a favourable interaction profile.

In general, the docking outcomes highlight the power of structure-based computational methods to determine potential drug candidates. Through the integration of binding affinity analysis with interaction analysis, this paper will show how *in silico* approaches can be used to inform the rational design of novel S1PR1 modulators. Since ligand 6 has good binding properties, it is an interesting candidate to undergo additional experimental validation, such as *in vitro* and *in vivo* experiments, to ensure the therapeutic potential of this ligand.

## REFERENCES

- [1] A. Compston and A. Coles, "Multiple sclerosis," *The Lancet*, vol. 372, no. 9648, pp. 1502–1517, 2008.
- [2] C. Confavreux and S. Vukusic, "Natural history of multiple sclerosis," *Brain*, vol. 129, pp. 606–616, 2006.
- [3] B. Hemmer, J. Kerschensteiner, and T. Korn, "Role of the immune system in MS," *Nat. Rev. Neurosci.*, vol. 16, pp. 545–558, 2015.
- [4] S. L. Hauser and J. R. Oksenberg, "The neurobiology of multiple sclerosis," *Neuron*, vol. 52, pp. 61–76, 2006.
- [5] J. Chun and V. Brinkmann, "Sphingosine-1-phosphate receptors in immune regulation," *Nat. Rev. Drug Discov.*, vol. 9, pp. 883–897, 2010.
- [6] V. Brinkmann et al., "Fingolimod (FTY720): discovery and mechanism," *Nat. Rev. Drug Discov.*, vol. 9, pp. 883–897, 2010.
- [7] H. Rosen and E. J. Goetzl, "S1P and immune cell trafficking," *Nat. Rev. Immunol.*, vol. 5, pp. 560–570, 2005.
- [8] B. D. Trapp and K. A. Nave, "Multiple sclerosis: axonal degeneration," *Annu. Rev. Neurosci.*, vol. 31, pp. 247–269, 2008.
- [9] S. M. Gold et al., "Mechanisms of neurodegeneration in MS," *Nat. Rev. Neurol.*, vol. 8, pp. 563–572, 2012.
- [10] R. M. Ransohoff, "Natalizumab for MS," *N. Engl. J. Med.*, vol. 356, pp. 2622–2629, 2007.
- [11] L. Steinman, "Immunology of MS," *Annu. Rev. Immunol.*, vol. 32, pp. 257–281, 2014.
- [12] B. Bielekova and R. Martin, "Development of MS therapies," *Nat. Rev. Drug Discov.*, vol. 3, pp. 585–598, 2004.
- [13] J. Cohen et al., "Oral fingolimod for relapsing MS," *N. Engl. J. Med.*, vol. 362, pp. 402–415, 2010.
- [14] L. Kappos et al., "Fingolimod vs placebo in MS," *N. Engl. J. Med.*, vol. 362, pp. 387–401, 2010.
- [15] T. Hla and V. Brinkmann, "S1P receptors: signaling and function," *J. Biol. Chem.*, vol. 286, pp. 9999–10003, 2011.

- [16] H. Chun et al., "S1P signaling in disease," *Annu. Rev. Pharmacol. Toxicol.*, vol. 53, pp. 95–120, 2013.
- [17] S. Spiegel and S. Milstien, "Sphingosine-1-phosphate signalling," *Nat. Rev. Mol. Cell Biol.*, vol. 4, pp. 397–407, 2003.
- [18] T. Schwab and M. Cyster, "Finding a way out: lymphocyte egress," *Nat. Immunol.*, vol. 8, pp. 1295–1301, 2007.
- [19] V. Brinkmann, "S1P receptor modulators in MS," *J. Neuroimmunol.*, vol. 308, pp. 1–8, 2017.
- [20] L. Matloubian et al., "Lymphocyte egress controlled by S1P receptor," *Nature*, vol. 427, pp. 355–360, 2004.
- [21] M. Mandala et al., "FTY720 mechanism," *Science*, vol. 296, pp. 346–349, 2002.
- [22] H. Cohen and V. Chun, "Fingolimod therapy overview," *Nat. Rev. Neurol.*, vol. 7, pp. 495–502, 2011.
- [23] FDA, "Fingolimod approval summary," 2010.
- [24] V. Brinkmann, "FTY720 mechanism of action," *Transplant. Proc.*, vol. 33, pp. 3078–3080, 2001.
- [25] A. Paugh et al., "Sphingosine kinase activity," *J. Biol. Chem.*, vol. 278, pp. 42952–42959, 2003.
- [26] D. Calabresi et al., "Safety of fingolimod," *Lancet Neurol.*, vol. 13, pp. 545–556, 2014.
- [27] S. Jain and A. Bhatti, "Adverse effects of S1PR modulators," *Drug Saf.*, vol. 40, pp. 321–332, 2017.
- [28] EMA, "Fingolimod safety profile," 2012.
- [29] M. Scott et al., "Limitations of fingolimod," *CNS Drugs*, vol. 30, pp. 1–10, 2016.
- [30] L. Kappos et al., "Siponimod in MS," *Lancet*, vol. 391, pp. 1263–1273, 2018.
- [31] J. Cohen et al., "Ozanimod trial," *Lancet Neurol.*, vol. 15, pp. 373–381, 2016.
- [32] R. Comi et al., "Selective S1PR modulators," *Mult. Scler. J.*, vol. 23, pp. 1084–1092, 2017.
- [33] S. Groves et al., "Neuroprotective role of S1P," *J. Neurosci.*, vol. 33, pp. 1878–1891, 2013.
- [34] M. Miron et al., "Remyelination and oligodendrocytes," *Nat. Neurosci.*, vol. 16, pp. 1211–1218, 2013.

- [35] R. Chun and H. Hartung, "S1P in CNS repair," *Lancet Neurol.*, vol. 9, pp. 111–120, 2010.
- [36] D. Kitchen et al., "Docking and scoring in drug design," *Nat. Rev. Drug Discov.*, 2004.
- [37] W. Walters et al., "Virtual screening overview," *J. Med. Chem.*, 1998.
- [38] P. Lionta et al., "Structure-based virtual screening," *Curr. Top. Med. Chem.*, 2014.
- [39] B. Lublin et al., "MS disease course," *Neurology*, 2014.
- [40] F. Dendrou et al., "Immunopathology of MS," *Nat. Rev. Immunol.*, 2015.
- [41] J. Goverman, "Autoimmune T cell responses," *Nat. Rev. Immunol.*, 2009.
- [42] C. Bjartmar et al., "Axonal damage in MS," *Ann. Neurol.*, 2003.
- [43] D. Mahad et al., "Mitochondrial dysfunction in MS," *Brain*, 2015.
- [44] H. Lassmann, "Neurodegeneration mechanisms," *J. Neurol. Sci.*, 2013.
- [45] T. Hla, "S1P signalling overview," *Science*, 2001.
- [46] M. Cyster and S. Schwab, "S1P gradients," *Annu. Rev. Immunol.*, 2012.
- [47] M. Camerer et al., "S1P and vascular integrity," *Nature*, 2009.
- [48] S. Sanchez et al., "S1P receptor biology," *J. Biol. Chem.*, 2003.
- [49] J. Pyne and S. Pyne, "S1P signalling pathways," *Nat. Rev. Cancer*, 2010.
- [50] E. Jaillard et al., "Oligodendrocyte survival," *Glia*, 2005.
- [51] J. Pelletier and D. Hafler, "MS therapeutics," *N. Engl. J. Med.*, 2012.
- [52] G. Scott et al., "New S1PR modulators," *Drugs*, 2016.
- [53] R. Pan et al., "Selective S1PR1 targeting," *J. Pharmacol. Exp. Ther.*, 2013.
- [54] Y. Tsukamoto et al., "Next-gen S1PR modulators," *Bioorg. Med. Chem.*, 2018.
- [55] I. Ferreira et al., "Molecular docking review," *Molecules*, 2015.
- [56] J. Bajorath, "Chemoinformatics in drug discovery," *Nat. Rev. Drug Discov.*, 2002.
- [57] A. Daina et al., "SwissADME tool," *Sci. Rep.*, 2017.

- [58] D. Pires et al., “pkCSM tool,” *J. Med. Chem.*, 2015.
- [59] J. Warren et al., “Docking limitations,” *J. Med. Chem.*, 2006.
- [60] L. Kappos et al., “Siponimod vs placebo in SPMS (EXPAND),” *Lancet*, 2018.
- [61] J. Cohen et al., “Ozanimod vs interferon beta-1a (RADIANCE),” *Lancet Neurol.*, 2016.
- [62] L. Kappos et al., “Ponesimod vs teriflunomide (OPTIMUM),” *JAMA Neurol.*, 2021.
- [63] M. A. Hanson et al., “Crystal structure of S1P1 receptor,” *Science*, 2012.
- [64] T. Hla and V. Brinkmann, “S1P receptor biology,” *Nat. Rev. Drug Discov.*, 2011.
- [65] I. Ferreira et al., “Molecular docking strategies,” *Molecules*, 2015.
- [66] W. L. Jorgensen, “Role of computation in drug discovery,” *Science*, 2004.
- [67] C. A. Lipinski et al., “Drug-likeness and Rule of Five,” *Adv. Drug Deliv. Rev.*, 2001.
- [68] J. B. Warren et al., “Docking scoring limitations,” *J. Med. Chem.*, 2006.

## LIST OF PUBLICATIONS

### 1. Conference Paper

Title of paper -“Computational Screening and Binding Analysis of Novel Emerging Small-Molecule S1PR1 Modulators for Multiple Sclerosis”

Author Names- Tanishka and Prof. Pravir Kumar

Name of the conference - Conference on Latest Innovations in Computing and Knowledge 2026 (CLICK 2026) Hindustan Institute of Technology and Science, Tamilnadu, India.

Date of Conference - 16th to 17th July 2026 at Hindustan Institute of Technology and Science, Tamilnadu, India

Indexing – IEEE

Status of paper – Accepted

Date of Acceptance – 30 April, 2026

Acceptance : 2026 IEEE  
- Conference on Latest  
Innovations in Computing and  
Knowledge 2026 (CLICK 2026) :  
Submission CLICK1072 has been  
created. Inbox



IEEE Conferen... Apr 30  
to me, pravirkumar ▾



Dear Author,

Greetings from 2026 IEEE - Conference on Latest  
Innovations in Computing and Knowledge 2026  
(CLICK 2026)

Paper id: CLICK2754

We are pleased to inform you that your above-  
mentioned paper has been accepted for Oral  
Presentation at the IEEE - Conference on Latest  
Innovations in Computing and Knowledge 2026  
(CLICK 2026), scheduled to be held from 16th to  
17th July 2026 at Hindustan Institute of  
Technology and Science, Tamilnadu, India, in  
Hybrid Mode. All the registered presented papers

# Computational Screening and Binding Analysis of Novel Emerging Small-Molecule S1PR1 Modulators for Multiple Sclerosis

Tanishka  
 Dept. of Biotechnology  
 Molecular Neuroscience and Functional Genomics  
 Delhi Technological University  
 Delhi 110042, India  
 tanishka\_24mscbio59@dtu.ac.in

Pravir Kumar  
 Dept. of Biotechnology  
 Molecular Neuroscience and Functional Genomics  
 Delhi Technological University  
 Delhi – 110042, India  
 Pravirkumar@dtu.ac.in

**Abstract**— The immune system triggers Multiple Sclerosis by stripping the nerves insulation, which blocks essential signaling between the brain and body. Myelin and axonal degeneration are key markers of MS, an inflammatory disease of the neural system. Despite the absence of a definitive therapeutic approach, several disease-modifying therapies (DMTs) focus on S1PRs, which play a crucial role in immune responses and vascular regulation, and functions as a functional modulator of S1PR1 to inhibit autoreactive lymphocytes from leaving In a shift away from injectable therapies, FTY720 became the first FDA-sanctioned oral agent specifically indicated for patients with MS. lymph nodes. While FTY720 represents a breakthrough in MS therapy, it does not work for all patients and requires long-term use. Despite its clinical efficacy, FTY720 treatment carries an increased risk of macular edema, cardiovascular complications, and increased risk of immunosuppression, necessitating regular ophthalmologic evaluations. It also requires in vivo phosphorylation to become biologically active, which may limit its therapeutic flexibility. These limitations highlight the need for alternative S1PR1 inhibitors with improved pharmacokinetic, safety, and efficacy profiles. In this study, we focus on identifying candidate compounds other than fingolimod as S1PR1 inhibitors. Molecular docking is used to analyze ligand–protein interactions, with ligands selected based on structural similarity to fingolimod and further evaluated through ADME analysis.

**Keywords**— Multiple Sclerosis; S1PR1; FTY720; conformation-Based therapeutic Design; Molecular Docking; Auto Dock Vina; Small-Molecule Modulators

## I. INTRODUCTION

As a long-term autoimmune pathology, MS involves a progressive attack on the body's neural framework [1]. The pathology involves an immune-driven breakdown of insulated nerve fibres, causing significant impairment to the integrity of the neural architecture [2]. A defining characteristic of MS is the occurrence of transient neurological deficits that eventually transition into a steady decline of nervous system function [3]. A growing range of successful interventions, such as selective sphingosine-1-phosphate modulators and various monoclonal antibodies, has been officially approved to alter the course of MS [4]. The S1PR family is becoming more well-known as a crucial mediator of numerous physiological processes, such as immunity, angiogenesis, inflammation, migration, survival, and cell differentiation. As a result, S1PRs have become important targets for multiple sclerosis, and fingolimod, a recently developed oral treatment that modulates S1PRs, has

been licensed for clinical usage [5]. Functional downregulation of S1PR in immune cells halt the egress of B cell and T cell from nodal tissues into lymphoid system [5]. In the context of disorders such as multiple sclerosis, the degradation of the myelin sheath is driven and progressive cerebral atrophy is contributed to by the migration of autoreactive lymphocytes into neural tissues.[6] Therefore, the goal of S1PR1-directed pharmacologic intervention is to keep these autoreactive lymphocytes in the lymph nodes and stop them from circulating and infiltrating the central nervous system. Sphingosine kinase-2 phosphorylates fingolimod (FTY720), a structural homolog of sphingosine, producing fingolimod phosphate in vivo. In central nervous system the phosphorylated form of FTY720 which binds to S1PR1 is inhibiting the trafficking of immune cells thus modulating S1PR1 binding in MS patients Neurodegeneration in multiple sclerosis encompasses not only demyelination but also axonal transection and neuronal death, which significantly contribute to the progression of permanent impairment [8]. S1P signaling not only has an immunomodulatory role but also affects endothelial barrier integrity and regulates lymphocyte trafficking throughout vascular and lymphatic systems, underscoring its therapeutic significance. [9]. Second-generation S1PR modulators, like Siponimod and ozanimod, have been engineered for enhanced receptor selectivity to mitigate deleterious effects linked to non-selective S1PR modulation. [10]. Moreover, recent research indicates that directly targeting S1PR1 may yield a better regulated immune response while reducing cardiovascular and off-target consequences associated with previous medications such as fingolimod. [9]. Multiple sclerosis pathogenesis is significantly influenced by changes in blood-brain barrier permeability, through which the entry of immune cells into the CNS is facilitated and inflammatory cascades are exacerbated [11]. Recent research has also emphasized the significance of sphingosine-1-phosphate signaling in neuroprotection, oligodendrocyte survival, and remyelination processes, indicating that it plays a dual function in immune regulation and CNS repair mechanisms.[12].Furthermore, targeted targeting of S1PR subtypes is seen to be a viable method for achieving treatment success while reducing side effects, especially those pertaining to pulmonary and cardiac functions.[13].Advances in computational techniques, including as molecular docking and in silico ADME prediction, have hastened the identification of new S1PR1 inhibitors with increased

binding affinity and drug-like characteristics, paving the way for the development of next-generation multiple sclerosis therapies.[14].

## II. MATERIALS AND METHODS

### A. Retrieval of Target Protein Structures

For the present in silico study, the 3D structure of target protein, S1PR1, was extracted from the Protein Data Bank(PDB) and prepared for subsequent computational studies (<https://www.rcsb.org>) [15]. The protein structures were selected based on their resolution and suitability for molecular docking studies. The downloaded structures were experimentally determined using X-ray crystallography, ensuring reliable structural accuracy for computational analysis.

### B. Preparation of Target Proteins

Initially, the PDB-obtained protein structures were accessible in PDB format. A part of MGL Tools called BOVIA DISCOVERY STUDIO VISUALIZER was used to prepare the proteins. All water molecules and unnecessary heteroatoms were eliminated from the protein structures prior to docking in order to prevent interference with the ligand binding analysis. In order to guarantee accurate interaction calculations, polar H-atoms were subsequently added to the protein structures along with proper charges [14]. In order to prepare the binding site for docking with the chosen ligands, any co-crystallized ligands in the structures were eliminated. In order to make the protein structures compatible with molecular docking software, they were finally saved in PDBQT format.

### C. Selection of Ligands

Swiss Similarity is an online tool for database mining. The goal of Swiss similarity was to virtually screen a number of small molecule libraries in a ligand-based manner. High throughput screening (HTS) is aided by Swiss similarity. Using fingolimod as the query molecule, this tool was utilized to mine the ZINC drug library using a structure similarity search. The query molecule was formatted in SMILES.

### D. Ligand Screening Based on ADME Properties

SwissADME (<http://www.com>) was used to further filter the compounds obtained from similarity screening based on pharmacokinetic and drug-like properties. ADME parameters—absorption, distribution, metabolism, and excretion—are important considerations when evaluating a compound's suitability for drug development, especially for central nervous system disorders like multiple sclerosis. Pan-assay interference compounds (PAINS), Brenk structural alerts, and Lipinski's rule of five were important screening criteria. Compounds were only deemed suitable for additional analysis if they satisfied acceptable thresholds for these parameters. This screening process made sure that the ligands that were shortlisted had good pharmacokinetic profiles and little chance of toxic or non-specific

interactions. For molecular docking studies, compounds that met all ADME-related requirements were chosen.

### E. Preparation of Ligands

All of the shortlisted ligands' three-dimensional (3D) structures were gathered in Structure Data File (SDF) format from publicly available chemical databases, such as PubChem. To guarantee compatibility with molecular docking studies, all ligand structures were then converted into PDBQT format using the Open Babel graphical user interface (GUI).

### F. Molecular Docking

PyRx was used to dock the ligand compounds with the target proteins easy dock vina is a very simple program to do this. it is designed to allow to dock multiple ligands against a particular protein. separate output files for each ligand in PDBQT format along with a excel file containing binding affinities of the ligands was made as a result of docking.

### G. Protein ligand complex analysis

Dassault Systems' BIOVIA Discovery Studio was used to analyze protein–ligand complexes. Both 2D and 3D representations of ligand-protein interactions were produced using the Discovery Studio 2021 Client. Proteins and ligands were input in PDBQT format. The interactions, including important binding residues and bonds, were structurally visualized, and the outcomes were extracted in two and three dimensions for in-depth examination.

## III. RESULTS AND ANALYSIS







### A. ADME analysis and preliminary screening

Swiss Similarity used structural similarity to shortlist compounds. Because of this search, 20 Compounds with a similarity score greater than 0.85 were found. These drugs were subsequently selected by ADME analysis utilizing various filters such BBB permeability, Lipinski, PAINS and Brenk. SwissADME was used to carry out this ADME analysis . observation which was consistent with all seven compounds. Further ADME evaluation utilized filters like , GI absorption permeability, Lipinski, pains and brenk alerts which were also considered to aid in determining the viability of the results.

### B. Visualizaion of docked ligands

Visualization of the docked ligand–S1PR1 complexes was performed using BIOVIA Discovery Studio to generate two-dimensional interaction diagrams. These diagrams were used to examine ligand orientation within the receptor binding pocket and to identify key intermolecular interactions. Differences in interaction patterns and binding poses were observed among the screened compounds, providing structural insight beyond docking scores alone. Supporting docking interaction analysis.

TABLE 1 : TABULAR REPRESENTATION OF IUPAC NAMES ,2D STRUCTURE AND BINDING AFFINITIES OF INTERACTING LIGANDS

PUBCH EM ID	IUPAC Name	2D Structure	Binding affinity( kj/mol)
107970 (REFER ENCE COMPO UND)	2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol		-7.3
1177962 9 (compou nd2)	4-[(1S,2R)-1-hydroxy-2-[[[(2R)-1-phenoxypropa n-2-yl] amino] propyl] phenol		-7.4
1101456 11 (compou nd3)	[(3Ar,6As)-5-phenylmethoxy-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl]-[4-(2-aminoethyl) phenyl] methanone		-7.6
1264428 07 (compou nd4)	2-[(2R)-4-[[4-(2-phenylethoxy) phenyl] methyl] morpholin-2-yl] ethanamine		-7.7
9589582 0 (compou nd5)	(1R)-1-[1-[[4-(2-aminoethyl) phenyl] methyl] piperidin-4-yl]-2-phenylethanol		-8.1
7705063 8 (compou nd6)	[(1R,3S)-1-amino-3-[(6R)-6-hexyl-5,6,7,8-tetrahydronap ththalen-2-yl]cyclopentyl]methanol		-8.8




Fig.1. Interaction between ligand no.1 i.e. Reference compound and target S1PR1




Fig. 2. Interaction between ligand no. 2 and target S1PR1




Fig. 3. Interaction between ligand no. 3 with target S1PR1



- [2] M. M. Goldenberg, "Multiple sclerosis review," *Pharmacy and Therapeutics*, vol. 37, no. 3, pp. 175–184, 2012.
- [3] S. L. Hauser and B. A. C. Cree, "Treatment of multiple sclerosis: A review," *The American Journal of Medicine*, vol. 133, no. 12, pp. 1380–1390.e2, 2020, doi: 10.1016/j.amjmed.2020.05.049.
- [4] F. Piehl, "Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis," *Journal of Internal Medicine*, vol. 289, no. 6, pp. 771–791, 2021, doi: 10.1111/joim.13273.
- [5] C. O'Sullivan and K. K. Dev, "The structure and function of the S1P1 receptor," *Trends in Pharmacological Sciences*, vol. 34, no. 7, pp. 401–412, 2013, doi: 10.1016/j.tips.2013.05.002.
- [6] T. Hla and V. Brinkmann, "Sphingosine 1-phosphate (S1P)," *Neurology*, vol. 76, no. 8 Suppl 3, pp. S3–S8, 2011, doi: 10.1212/WNL.0b013e31820d5cc1.
- [7] W. Wang, M.-C. Huang, and E. J. Goetzl, "Type 1 sphingosine 1-phosphate G protein-coupled receptor (S1P1) mediation of enhanced IL-4 generation by CD4 T cells from S1P1 transgenic mice," *The Journal of Immunology*, vol. 178, no. 8, pp. 4885–4890, 2007, doi: 10.4049/jimmunol.178.8.4885.
- [8] B. D. Trapp and K.-A. Nave, "Multiple sclerosis: An immune or neurodegenerative disorder?," *Annual Review of Neuroscience*, vol. 31, pp. 247–269, 2008.
- [9] V. Brinkmann, "Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology," *Pharmacology & Therapeutics*, vol. 115, no. 1, pp. 84–105, 2007.
- [10] R. C. Scott *et al.*, "Emerging S1P receptor modulators for multiple sclerosis treatment," *CNS Drugs*, vol. 30, pp. 765–778, 2016.
- [11] C. Laroche, J. I. Alvarez, and A. Prat, "How do immune cells overcome the blood-brain barrier in multiple sclerosis?," *FEBS Letters*, vol. 585, no. 23, pp. 3770–3780, 2011.
- [12] M. Miron *et al.*, "Fingolimod (FTY720) enhances remyelination following demyelination," *Journal of Neuroscience*, vol. 30, no. 42, pp. 13910–13919, 2010.
- [13] E. J. Gergely *et al.*, "Selective S1P receptor modulators in multiple sclerosis therapy," *Drugs*, vol. 72, no. 12, pp. 1645–1656, 2012.
- [14] D. Ferreira *et al.*, "In silico drug design and molecular docking in modern drug discovery," *Current Drug Targets*, vol. 16, no. 5, pp. 1–15, 2015.
- [15] S. K. Burley *et al.*, "RCSB Protein Data Bank: Powerful new tools for exploring 3D structures of biological macromolecules," *Nucleic Acids Research*, vol. 49, pp. D437–D451, 2021.



## DELHI TECHNOLOGICAL UNIVERSITY

(Formerly Delhi college of Engineering)

Shahbad Daulatpur, Main Bawana Road, Delhi-42

### PLAGIARISM VERIFICATION

Title of Thesis “**Computational Screening and Binding Analysis of Novel Emerging Small-Molecule S1PR1 Modulators for Multiple Sclerosis**” Total Pages **53** Name of the scholar **Tanishka (24/MSCBIO/59)**.

Supervisor

Prof. Pravir Kumar

Department of Biotechnology

This is to report that the above thesis was scanned for similarity detection. Process and outcome is given below :

Software used: **Turnitin**, Similarity Index: **5%**, Total Word Count: **14,567**

Date:

**Candidate's Signature**

**Supervisor's Signature**

# Pravir Kumar

## Tanishka pdf

Apurva

### Document Details

Submission ID  
trn:old::27535:137172891

Submission Date  
Apr 30, 2026, 12:20 PM GMT+5:30

Download Date  
Apr 30, 2026, 12:29 PM GMT+5:30

File Name  
Tanishka pdf.pdf

File Size  
898.0 KB

51 Pages

14,018 Words

82,004 Characters



Page 1 of 57 - Cover Page

Submission ID trn:old::27535:137172891



Page 2 of 57 - Integrity Overview

Submission ID trn:old::27535:137172891

## 5% Overall Similarity

The combined total of all matches, including overlapping sources, for each database.

### Filtered from the Report

- Bibliography
- Quoted Text
- Cited Text
- Small Matches (less than 8 words)

### Exclusions

- 2 Excluded Matches

### Match Groups

- 63 Not Cited or Quoted 5%  
Matches with neither in-text citation nor quotation marks
- 0 Missing Quotations 0%  
Matches that are still very similar to source material
- 0 Missing Citation 0%  
Matches that have quotation marks, but no in-text citation
- 0 Cited and Quoted 0%  
Matches with in-text citation present, but no quotation marks

### Top Sources

- 4% Internet sources
- 3% Publications
- 3% Submitted works (Student Papers)


### Integrity Flags


0 Integrity Flags for Review

Our system's algorithms look deeply at a document for any inconsistencies that would set it apart from a normal submission. If we notice something strange, we flag it for you to review.

A Flag is not necessarily an indicator of a problem. However, we'd recommend you focus your attention there for further review.

# Tanishka

 +9992274727

 tanishkaduhan@gmail.com

## EDUCATION

- Aug 2024 – Jun 2025( Expected)  
M.Sc. Biotechnology, Delhi Technological University
- Nov. 2021- Jun 2024  
B.Sc. Life Science, Chaudhary Ranbir Singh University, Jind (Haryana)

## Skills and Interests

- Skilled in communication, teamwork and academic presentation with the ability to work efficiently in both individual and group environments.
- Possess strong problem-solving abilities, time management skills and adaptability in learning new scientific concepts and laboratory techniques.
- Proficient in MS Word, PowerPoint, scientific documentation and basic computational tools used in biotechnology studies.
- Interested in biotechnology, molecular biology, genetics, microbiology and computational biology with a keen enthusiasm for scientific innovation and modern healthcare technologies.

### **Undertaking**

I am taking full responsibilities of this project work and thesis written for my dissertation. This thesis is neither copied from any place or written AI/Chat GPT assisted manner. In case of any discrepancies and falsified information my degree may be cancelled.

I will take responsibilities of the dissertation if something found wrong take any appropriate action.

Name of Student

Roll.No.

Signature